Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518584], Inc.  CONFIDENTIAL  Page 1 of 62   
   
  
Phase 1/2 Trial Evaluating the Safety and Tolerability of 
NanoDoce® Injection and Intravesical Instillation in 
Subjects with Urothelial C arcinoma  
 
Protocol Identifying Number: NANODOCE-2 017-02 
Principal Investigator:  [INVESTIGATOR_411191], MD, FACS  
IND Sponsor: NanOlogy, LLC  
IND #: 137404  
Version Number:  7.0 
18 June 2020 
 
  
 
   
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518585] OF ABBREVIATIONS  ....................................................................................................................................... 5  
SPONSOR SIGNATURE [CONTACT_1783]  ............................................................................................................................... 7  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 8  
PROTOCOL SUMMARY  ........................................................................................................................................... 9  
Figure 1: Cohort Schedule – Group 1 – NMIBC  ................................................................................................... 12 
Figure 2: Cohort Schedule – Group 2 – MIBC ...................................................................................................... 13 
1 KEY ROLES  .................................................................................................................................................. 14 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................... 16 
2.1 Background Information  .................................................................................................................... 16 
2.2 Rationale  ............................................................................................................................................. 18 
2.3 Potential Risks and Benefits  ............................................................................................................ 19 
2.3.1  Known Potential Risks  ................................................................................................... 19 
2.3.2  Known Potential Benefits  .............................................................................................. 19 
3 OBJECTIVES AND PURPOSE  .................................................................................................................. 19 
4 STUDY DESIGN AND ENDPOINTS  ......................................................................................................... 19 
4.1 Description of the Study Design  ...................................................................................................... 19 
4.2 Endpoints  ............................................................................................................................................ 21 
4.2.1  Primary Endpoint  ............................................................................................................ 21 
4.2.2  Seco ndary Endpoints  .................................................................................................... 21 
4.2.3  Exploratory Endpoints  ................................................................................................... 21 
5 STUDY ENROLLMENT AND WITHDRAWAL  ......................................................................................... 21 
5.1 Participant Inclusion Criteria ............................................................................................................ 21 
5.2 Participant Exclusion Criteria ........................................................................................................... 22 
5.3 Strategies for Recruitment and Retention  ...................................................................................... 22 
5.4 Participant Withdrawal or Termination  ............................................................................................ 23 
5.4.1  Reasons for Withdrawal or Termination  ..................................................................... 23 
5.4.2  Handling of Participant Withdrawals or Termination  ................................................. 23 
5.5 Premature Termination or Suspension of Study  ........................................................................... 23 
6 STUDY DRUG  .............................................................................................................................................. 24 
6.1 Study drug(s) and Control Description  ........................................................................................... [ADDRESS_518586] Storage and Stability  ....................................................................................... 25 
6.1.4  Preparation  ...................................................................................................................... 26 
6.1.5  Dosing and Administration  ............................................................................................ 26 
6.1.6  Route of Administration  ................................................................................................. 27 
6.1.7  Starting Dose and Dose Escalation Schedule  ........................................................... 27 
6.1.8  Dose Adjustments/Modifications/Delays  .................................................................... 30 
6.1.9  Duration of Therapy  ....................................................................................................... 30 
6.1.10  Tracking of Dose  ............................................................................................................ 30 
6.1.11  Device Specific Considerations  ................................................................................... 30 
6.2 Study drug A ccountability Procedures ............................................................................................ 30 
7 STUDY PROCEDURES AND SCHEDULE  .............................................................................................. 31 
7.1 Study Procedures/Evaluations  ......................................................................................................... 31 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518587] of Care Study Procedures  ........................................................................... 31 
7.2 Laboratory Procedures/Evaluations  ................................................................................................ 32 
7.2.1  Clinical Laboratory Evaluations  .................................................................................... 32 
7.2.2  Other Assays or Procedures  ........................................................................................ 32 
7.3 Study Schedule  .................................................................................................................................. 33 
7.3.1  Screening (Visit 1)  .......................................................................................................... 33 
7.3.2  Trans Urethral Resection of Bladder Tumor (Visit 2)  ................................................ 34 
7.3.3  NanoDoce Treatment - Injection & Intravesical Instillation (Visit 2 continued)  ..... 34 
7.3.4  Visit 3  35 
7.3.5  Induction Period (Visits 4 – 9) ...................................................................................... 35 
7.3.6  Maintenance Period (Visits 10 – 12) ........................................................................... 36 
7.3.7  End of Treatment  ........................................................................................................... 37 
7.3.8  Safety Assessment Visit ................................................................................................ 38 
7.3.9  Early Termination Visit  .................................................................................................. 38 
7.3.10  SURVIVAL/PROGRESSION FOLLOW- UP ............................................................... 38 
7.3.11  Unscheduled Visits  ........................................................................................................ 38 
7.3.10  Schedule of Events Table  ............................................................................................. 39 
7.4 Justification for Sensitive Procedures  ............................................................................................. 43 
7.5 Concomitant Medications, Treatments, and Procedures  ............................................................. 43 
7.6 Precautionary Medications, Treatments, and Procedures  .......................................................... 43 
7.7 Prohibited Medications, Treatments, and Procedures  ................................................................. 43 
7.8 Prophylactic Med ications, Treatments, and Procedures  ............................................................. 43 
7.9 Rescue Medications, Treatments, and Procedures  ..................................................................... 44 
7.10  Participant Access to Study drug At Study Closure ...................................................................... 44 
8 ASSESSMENT OF SAFETY  ...................................................................................................................... 44 
8.1 Specif ication of Safety Parameters  ................................................................................................. 44 
8.1.1  Definition of Adverse Events (AE)  ............................................................................... 45 
8.1.2  Definition of Serious Adverse Events (SAE)  .............................................................. 45 
8.1.3  Definition of Unanticipated Problems (UP)  ................................................................. [ADDRESS_518588]  ............................................................................................. 48 
8.4.5  Reporting of Pregnancy  ................................................................................................ 48 
8.5 Study Halting Rules  ........................................................................................................................... 48 
8.6 Safety Oversight  ................................................................................................................................ 49 
9 CLINICAL MONI TORING  ............................................................................................................................ 49 
10 STATISTICAL CONSIDERATIONS  .......................................................................................................... 50 
10.1  Statistical and Analytical Plans  ........................................................................................................ 50 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518589], Inc.  CONFIDENTIAL  Page 4 of 62 10.2  Statistical Hypotheses  ....................................................................................................................... 50 
10.3  Analysis Datasets  .............................................................................................................................. 50 
10.3.1  Missing  Data  ................................................................................................................... 50 
10.4  Description of Statistical Methods  ................................................................................................... 50 
10.4.1  General Approach  .......................................................................................................... 50 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 50 
10.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 51 
10.4.4  Safety Analyses  .............................................................................................................. 51 
10.4.5  Adherence and Retention Analyses  ............................................................................ 52 
10.4.6  Baseline Descriptive Statistics  ..................................................................................... 52 
10.4.7  Planned Interim Analyses  ............................................................................................. 52 
10.4.8  Additional Sub- Group Analyses  ................................................................................... 53 
10.4.9  Multiple Comparison/Multiplicity ................................................................................... 53 
10.4.10  Tabulation of Individual Response Data  ..................................................................... 53 
10.4.11  Exploratory Analyses  ..................................................................................................... 53 
10.4.12  Concomitant Medication ................................................................................................ 53 
10.5  Sample Size  ....................................................................................................................................... 54 
10.6  Measures to Minimize Bias  .............................................................................................................. 54 
10.6.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 54 
10.6.2  Evaluation of Success of Blinding  ............................................................................... 54 
10.6.3  Breaking the Study Blind/Participant Code  ................................................................ 54 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 54 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................. 55 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_518590]  ................................................................................................................ 55 
13.3  Informed Consent Process  ............................................................................................................... 56 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ... [ADDRESS_518591] POLICY  .......................................................................................................... 59 
17  LIABILITY AND INSURANC E .................................................................................................................... 59 
18  LITERATURE REFERENCES .................................................................................................................... 60 
APPENDIX A: ECOG Performance Scale  ............................................................................................................ 62 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518592] Aspartate Tran saminase  
BCG  Bacillus Calmette –Guérin  
BUN  Blood Urea Nitrogen  
CBC Complete Blood Count  
CFR Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Comprehensive Metabolic Panel  
CO2  Carbon Dioxide  
CR Complete Response  
CRO  Clinical Research Organization  
CT Computed Tomography Scan  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT Dose -Limiting Toxicity  
DSMB  Data Safety Monitoring Board  
ECG Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EDC Electronic Data Capture  System  
eCRF  Electronic Case Report Form  
EMR  Electronic Medical Record  
FDA The U.S. Food and Drug Administration  
GCP Good Clinical Practice  
GLP Good Laboratory Practice  
Hct Hematocrit  
Hgb Hemoglobin  
ICF Informed Consent Form  
ICH International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
ICMJE  International Committee of Medical Journal Editors  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISF Investigator Site File  
IT Intratumoral  
ITV Intravesical  
IV Intravenous  
LDH Lactate Dehydrogenase  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCV  Mean Corpuscular Volume  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518593] Inc.  CONFIDENTIAL  Page 6 of 62 MedDRA  Medical Dictionary for Regulatory Activities  
MIBC  Muscle Invasive Bladder Cancer  
MFD  Maximum Feasible Dose  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NDA  New Drug Application  (Marketing Application)  
NF National Formulary  
NMIBC  Non -Muscle Invasive Bladder Cancer  
NOAEL  No-Adverse Effect Level  
OS Overall Survival  
PCA Precipi[INVESTIGATOR_411192] -free Survival  
pH Potential of Hydrogen  
PI [INVESTIGATOR_411193] -emergent Adverse Event  
TURBT  Trans -urethral resection of bladder tumor  
ULN  Upper Limit of Normal  
UP Unanticipated Problem  
USP [LOCATION_002] Pharmacopeia  
UTI Urinary Tract Infection  
WBC  White Blood Cell  
WHO  World Health Organization  
 
   
Phase 1/2 NanoDoce® Trial in Subjects with Urothelial Carcinoma  Version 7.[ADDRESS_518594] Inc. CONFIDENTIAL  Page 7 of 62 SPONSOR SIGNATURE [CONTACT_16805]: Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and 
Intravesical Instillation in Subjects with Urothelial Carcinoma 
Protocol Number:  NANODOCE-2017-02 
Version Number:   7.0 
Date:  18 June 2020 
IND Number:   [ADDRESS_518595]:  NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension 
Sponsor:  NanOlogy, LLC  
 [ADDRESS_518596]., Suite 240 
 San Luis Obispo, CA [ZIP_CODE] 
 [PHONE_8488] 
The Sponsor for IND 137404, NanOlogy, LLC, has transferred responsibility for all obligations set forth in [ADDRESS_518597] to the IND; in accordance with [ADDRESS_518598] to all activities related to the IND. 
   - Name [CONTACT_13693]:  
Gere diZerega, MD  
President & CEO, US Biotest, Inc.  
 
__________________________________________  __________________________ 
   Date 
 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518599] the 
confidentiality of the document.  
The signature [CONTACT_114117] [INVESTIGATOR_411194]/her agreement.  
 
 __________________________________________  __________________________  
Signature [CONTACT_789]   [CONTACT_1782]  
 
 
__________________________________________  
Printed Name [CONTACT_789]  
 
 
[CONTACT_7609] 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518600] Inc.  CONFIDENTIAL  Page 9 of 62 PROTOCOL SUMMARY  
Title:  Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce ® Injection and Intravesical  
Instillation in Subjects with Urothelial Carcinoma  
 
 
Précis:  In this open- label, dose rising, phase 1/2 trial, subjects with high -risk non-muscle invasive 
bladder cancer ( NMIBC) or muscle invasive bladder cancer ( MIBC ), will receive NanoDoce  
(sterile nanoparticulate docetaxel ) Powder for Suspension  as a direct injection to the bladder 
wall and intravesical instillation (s). Subjects will be stratified into two treatment groups, 
Group 1 ( NMIBC)  and Group 2 ( MIBC) . At Visit 2, all subjects will r eceive NanoDoce  injected  
into the index tumor resection site on the bladder wall , immediately following transurethral 
resection of the bladder tumor (TURBT) , followed by [CONTACT_411210]  (within [ADDRESS_518601] in jection) .  
Group 1 (NMIBC)  and Group 2 (MIBC) Subset  
Subjects will be assessed for recovery (TURBT resection site healing) at Visit  4, at which point 
the Investigator will evaluate subject symptoms, pathology (if available), gross hematuria or 
urinalysis findings.  If the Investigator determines that the subject has sufficiently recovered, 
the subject will enter a [ADDRESS_518602] administration of NanoDoce if 
the End of Treatment visit is not conducted. 
Progression, progression -free survival  (PFS) and post -study concomitant therapy will be 
collected at [ADDRESS_518603] 
retained their bladders  (non -cystectomy subjects) . 
Subjects will be evaluated for tumor recurrence or disease progression  with cystoscopy  and 
urine cytology  at Visit 10, End of Treatment , or at any time, at the discretion of the 
Investigator . Biopsy is to be performed at any time at the discretion of the Investigator  for 
positive or suspi[INVESTIGATOR_411195] . Subjects will be followed through End 
of Treatment visit for safety , PFS  and tumor response to therapy . Institution pathology data  
will be collected for any resection, cystectomy or biopsy speci men (to include, but not limited 
to bladder resection , cystectomy or node tissue)  at any time during the study or early 
withdrawal .   
Group 2 ( MIBC)  
At the end of Visit 3 , Group 2 (MIBC) subjects will proceed to institutional standard of care 
treatments and return for the  End of T reatment study visit 45 days (+/ - 5 days) after V isit 2. 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518604] of c are chemotherapy or 
treatment, may be offered intravesical chemotherapy  in the I nduction and Maintenance 
periods as described for Group 1 in this  study  (referred to hereafter as the “Grou p 2 Subset”) .  
Progression, PFS and post -study concomitant therapy will be collected at 6, [ADDRESS_518605] retained their bladders (non-
cystectomy subjects). 
Groups [ADDRESS_518606] 
injection of NanoDoce co ncentrations  (0.75, 1.5, 2.5, or 3.75 mg/mL)  for Group s [ADDRESS_518607] concentration .  
The study will also dose escalate Group s 1 and 2 for the intravesical instillation of NanoDoce 
concentrations  (2.0 and 3.0 mg/mL) . In the intravesical instillation dose escalation phase, all 
subjects in Group [ADDRESS_518608] concentration of 2.0 mg/mL for the V isit 2 
instillation.  If the dose is well -tolerated, Group 1 subjects will continue to receive 2.0 mg/mL 
until Induction visit # 6, then escalat e to 3.0 mg/mL intravesical instillations for t he 
subsequent Induction and Maintenance intravesical instillations . Group [ADDRESS_518609] concentration of 2.0 mg/mL for the Visit [ADDRESS_518610] 
Injection dose s. If the dose is well -tolerated, Group 2 subjects will  escalate to 3.0 mg/mL 
intravesical instillations for the dose confirmation portion of the study.  For the subset of  
Group 2 subjects proceeding to the Induction and Maintenance regimen, intravesical instillation escalation to 3.0 mg/mL will also be determi ned after Visit 6.  
Following Data Safety Monito ring Board (DSMB) review of the cohort data, with the 
exception of the PK data , the DSMB will determine whether to: (a) escalate to the next dose 
level cohort (no DLT); (b) add three additional subjects to the current cohort (one DLT); (c) if 
still at the first cohort, stop the study (2 or more DLT); (d) if at higher cohorts,  return to the 
previous (lower) dose cohort and expand by [CONTACT_411211] ( more than one DLT). The dose 
determin ed to be most suitable for further evaluation, defined as the highest dose with an 
acceptable safety and tolerability profile (as determined by [CONTACT_4318]) will enroll additional 
subjects to total  up to [ADDRESS_518611] injection dose level.   
Objectives:  
 Primary objective:  
• To evaluate the safety and tolerability of NanoDoce injected directly into the 
bladder wall  and instilled intravesically . 
 
 Secondary objectives:  
• To characterize  the PK of docetaxel  when injected directly into the bladder wall, in 
the presence of NanoDoce  intravesical  instillation . 
• To determine whether any of the NanoDoce  concentrations  (0.75, 1.5, 2.5, or 3.75 
mg/mL ) in the presence of NanoDoce intravesical instillation concentration dose of 
2.0 or 3.0 mg/mL, shows signs of preliminary efficacy . 
 
Endpoint s: Primary endpoint: Safety and tolerability as demonstrated by [CONTACT_20721]  (AE), changes in 
laboratory assessme nts, physical examination findings  and vital signs.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518612] Inc.  CONFIDENTIAL  Page 11 of 62  
 Secondary endpoints:  
• Concentration of docetaxel  in the syst emic circulation post -injection, in the 
presence of intravesical  instillation (as determined by [CONTACT_411212]);  
• PFS defined as t umor recurrence  or disease progression at Visit 10 and Visit 13;  
• Overall survival (OS) determined by [CONTACT_411213] 12 months following Visit 4. 
 
Population:  Group 1: Up to 42 subjects with NMIBC ; 
Group 2: Up to 33 subjects  with MIBC. 
 
Phase:  Phase 1/2 
 
Number of 
Sites enrolling 
participants :  Five 
Description of 
Study Drug : NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension at concentrations of 
0.75 1.5, 2.5, or 3.75 mg/mL  administered by [CONTACT_411214] ; 2.0 mg/mL or 3.0 mg/mL 
administered by [CONTACT_137439].  
 
Study Duration:  Up to 30 months.  
 
Participa nt 
Duration:  Group 1: Estimated up to 33 weeks , including safety assessments . 
Group 2: Estimated up to 64 days , including safety assessments.  
Group 2 Subset: Estimated up to 33 weeks , including safety assessments . 
Data collection only : at 6 (Group 2) , 9 and 12 months . 
 
  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518613] Inc.  CONFIDENTIAL  Page 12 of 62 FIGURE 1: COHORT SCHEDULE  – GROUP 1 – NMIBC   
 
 
 
  
 
 
 
 
 
              
  0.75 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  
0 DLT  0 DLT  0 DLT  
0 DLT  ≥ 2 DLT  
≥ 2 DLT  
1 DLT  1 DLT  +1 DLT  
+1 DLT  ITV #4  
+3 Subjects  
Enroll up to 9 total subjects at maximum tolerated dose  0 DLT  
0 DLT  ≥ 2 DLT  1 DLT  +1 DLT  
DOSE CONFIRMATION PHASE  STOP  
0.75 mg/mL DI 
3.0 mg/mL ITV  0.75 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  
0.75 mg/mL DI 
3.0 mg/mL ITV  0 DLT  
≥ 2 DLT  
+1 DLT  +3 Subjects  
1.5 mg/mL DI 
2.0 mg/mL ITV  
0 DLT  1 DLT  1.5 mg/mL DI 
2.0 mg/mL ITV  
ITV #4  
1.5 mg/mL DI 
3.0 mg/mL ITV  +3 Subjects  
1.5 mg/mL DI 
3.0 mg/mL ITV  
+3 Subjects  2.5 mg/mL DI 
2.0 mg/mL ITV  +3 Subjects  
1 DLT  ≥ 2 DLT  
+1 DLT  
ITV #4  
2.5 mg/mL DI 
3.0 mg/mL ITV  2.5 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  
+3 Subjects  
3.75 mg/mL DI 
2.0 mg/mL ITV  1 DLT  ≥ 2 DLT  
+1 DLT  
2.5 mg/mL DI 
3.0 mg/mL ITV  
+3 Subjects  
3.75 mg/mL DI 
3.0 mg/mL ITV  ≥ 2 DLT  
+1 DLT  1 DLT  
3.75 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  
3.75 mg/mL DI 
3.0 mg/mL ITV  0 DLT  0 DLT  0 DLT  
ITV #4  0 DLT  0 DLT  0 DLT  0 DLT  0 DLT  
≥ 2 DLT  
+1 DLT  1 DLT  
DOSE ESCALATION PHASE  
GROUP 1 - NMIBC  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518614] Inc.  CONFIDENTIAL  Page 13 of 62 FIGURE 2: COHORT SCH EDULE – GROUP 2 – MIBC  
 
   0.75 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  STOP  
1.5 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  
2.5 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  
3.75 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  0.75 mg/mL DI 
2.0 mg/mL ITV  
1.5 mg/mL DI 
2.0 mg/mL ITV  
2.5 mg/mL DI 
2.0 mg/mL ITV  
+3 Subjects  3.75 mg/mL DI 
2.0 mg/mL ITV  3.75 mg/mL DI 
3.0 mg/mL ITV  0 DLT  
0 DLT  
0 DLT  
0 DLT  
0 DLT  0 DLT  0 DLT  0 DLT  0 DLT  1 DLT  
1 DLT  
1 DLT  
1 DLT  
1 DLT  ≥ 2 DLT  
≥ 2 DLT  
≥ 2 DLT  
≥ 2 DLT  
≥ 2 DLT  +1 DLT  
+1 DLT  
+1 DLT  
+1 DLT  
+1 DLT  
Enroll up to 9 total Group 2/Group 2 subset 
subjects at MTD dose 
DOSE CONFIRMATION PHASE  
DOSE ESCALATION PHASE  
GROUP 2 - MIBC  +3 Subjects  
+3 Subjects  
+3 Subjects  
+3 Subjects  
3.75 mg/mL DI 
3.0 mg/mL ITV  0 DLT  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518615] Inc.  CONFIDENTIAL  Page 14 of 62  
1 KEY ROLES  
Medical Director  
Gere diZerega, MD  
President & CEO, US Biotest, Inc.  
Professor, USC Keck School of Medicine  
[ADDRESS_518616]., Suite 240, San Luis Obispo, CA [ZIP_CODE]  
805- 630- 2800  
[EMAIL_7837] 
Study Manager 
Rose Marie Cavanna- Mast, RT CCRA  
US Biotest, Inc.  
[ADDRESS_518617]., Suite 240, San Luis Obispo, CA [ZIP_CODE]  
805- 595- 1300  
[EMAIL_7838]  
Principal Investigator  
[INVESTIGATOR_411196] , MD, FACS  
President, BCG Oncology  Clinical  [CONTACT_40758] of Arizona College of Medicine  
[ADDRESS_518618]  
Phoenix, AZ [ZIP_CODE]  
[EMAIL_7839]  
Medical Monitor  
Antony Verco, MD  
US Biotest, Inc.  [ADDRESS_518619]., Suite 240, San Luis Obispo, CA [ZIP_CODE]  
805- 235- 9193  
[EMAIL_7840] 
Laboratory – PK Samples  
Covance Madison Laboratories Bioanalytical (BA) Group  [ADDRESS_518620], Madison, WI [ZIP_CODE]  
608- 442- 8200  
Laboratory – IHC Samples  
NeoGenomics Laboratories Inc.  
Pharma Services Department  
31 Aliso Viejo, CA [ZIP_CODE]  
[PHONE_8489] Ext 7103  
 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518621] Inc.  CONFIDENTIAL  Page 15 of 62   
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518622] Inc.  CONFIDENTIAL  Page 16 of 62 2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIO NALE  
 
2.1 BACKGROUND INFORMATI ON  
The Sponsor for IND 137404, NanOlogy , LLC  (NanOlogy) , has transferred responsibility for all obligations set forth in 
21 CFR Part 312 to US Biotes t, Inc.  (US Biotest), with regard to the IND. In accordance with [ADDRESS_518623] to all activities related to the IND. Therefore, references to 
“Sponsor” hereafter in this protocol refer to US Biotest, Inc.  
Name [CONTACT_411259] : 
NanOlogy, LLC  has produced a formulation of nanoparticulate doce taxel, identified as NanoDoce ® (sterile 
nanoparticulate docetaxel ) Powder for Suspension ( NanoDoce ). NanoDoce  is manufactured using a Precipi[INVESTIGATOR_411197] (PCA) technique that employs supercritical carbon dioxide and acetone to generate 
docetaxel  nanoparticles within a well -characterized particle -size distribution. Following PCA, NanoDoce  is filled into a 
clear 60mL Type 1, USP , clear -glass vial ( 100 mg/vial) as a powder fill of nanoparticulate docet axel, closed with a 
bromobutyl rubber stopper and aluminum crimp seal, and ster ilized by [CONTACT_411215]. Prior to administration , 
NanoDoce  will be reconstituted with Sterile Reconstitution Solution (1% Polysorbate 80 and 8% Ethanol in 0.9% 
Sodium Chloride for Injection, USP ), to form a suspension. The suspension will be further diluted with different 
volumes of 0.9% Sodium Chloride for Injection, USP  to achieve the final dose formulation s. The reconstitution and 
dilution will be performed at the investigation site p harmacy.  
Nonclinical Summary:  
NanOlogy conducted one in vivo  nonclinical pharmacology study to determine the effects of intratumoral (IT) 
injection of NanoDoce on a urinary bladder transitional cell carcinoma subcutaneous xenograft in an immunocompromised nude mouse model . The objective of Study D -PBl-02-2017,  Effect of IT administered NanoDoce 
on growth of Subcutaneous (SC) UM -UC-3 Bladder Cancer in Immunocompromised (Hsd:Athymic Nude- Foxn1nu nude) 
Mice , was to evaluate the effect of one, two, or three weekly IT administrations of NanoDoce (100 mg/kg)  on tumor 
grow th in comparison to IT vehicle and intravenous (IV) chemotherapy (docetaxel ; 30 mg/kg) controls. Treatment 
outcome was based on differences in tumor volume. Two or three weekly IT NanoDoce administrations were more effective than IV docetaxel in inhibiting the progression of urinary bladder carcinoma. Systemic toxicity leading to 
weight loss occurred in animals treated with three cycles of IV docetaxel or three cycles of IT NanoDoce; one or two cycles of IT NanoDoce did not affect weight gain. Evaluation of  tissue from the tumor sites showed that IT 
administration of NanoDoce provided appreciable docetaxel levels for durations of up to 44 days  following 
administration . 
NanOlogy conducted two  in vivo  nonclinical pharmacology study to determine the effects of NanoDoce on renal  cell 
carcinoma . The objective of Study PD -Pre-03-2018,  A drug efficacy study in the Sprague- Dawley Rag2; Il2rg null (SRG) 
rat xenograft model of Human renal cell Adenocarcinoma ( 786- O), was to evaluate the effect of one, two, or three 
weekly IT administrations of NanoDoce (20 mg/kg) on tumor growth in comparison to IT vehicle and IV chemotherapy (docetaxel; 2.5 -5 mg/kg) controls. Treatment outcome was based on differences in tumor  volume. 
One, t wo, and three weekly IT NanoDoce administrations were more effective than IV docetaxel i n inhibiting the 
progression of renal cell carcinoma. The IT NanoDoce groups (female) showed almost no/no evidence of tumor on completion of study. NanOl ogy also conducted Study Number D -PRe-05-2018, Evaluation of the Efficacy of 
Intratumoral NanoDoce against Primary and Secondary Renca Renal Cell Carcinoma in BALB/c Mice. The Renca 
model of mouse renal cell carcinoma  was used to evaluate  the efficacy of IT NanoDoce against primary and 
secondary tumors compared to untreated and vehicle -treated mice and mice treated with IV  docetaxel.  NanoDoce 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518624] Inc.  CONFIDENTIAL  Page 17 of 62 administered IT and intratumoral/peritumoral at 30 mg/kg and 60 mg/kg achieved potential therapeut ic activity , 
defined as tumor growth inhibition > 60%. With the exception of 60 mg/kg administered IT, all NanoDoce had 
significantly greater tumor growth inhibition compared  to IV docetaxel ( p < 0.01 ). 
To support development of NanoDoce for an indication of treatment of genitourinary neoplasms, seven  nonclinical 
toxicology studies were conducted.  Two studies (non- GLP Study D -TR-03-2017 and GLP Study D -TR-04-2017) 
evaluated the effects of up to four weekly repeat -dose intravesical instillations of NanoDoce  suspensions at 1.6 
mg/mL (3.2 mg/kg), 5 mg/mL (10 mg/kg), 15 mg/mL (30 mg/kg) or 40 mg/mL (80 mg/kg) into the urinary bladder of female rats. The maximum tolerated dose (MTD) and no -observed -adverse- effect -level  (NOAEL) for four weekly 
NanoDoce intravesical instillations was determined to be 40 mg/mL, which is also the maximum feasible dose (MFD) based on NanoDoce solubility.  Two studies (non- GLP Study D -TRab -02-2017 and GLP Study D -TRab -03-2017) were 
conducted to evaluate the effects of a single direct i ntramural injection of NanoDoce into the urinary bladder wall in 
male and female rabbits. NanoDoce was administered at the following doses: 1.6 mg/mL (0.48 mg/kg), 5 mg/mL (1.5 mg/kg), 15 mg/mL (4.5 mg/kg), or 40 mg/mL (12 mg/kg). The MTD was determined to  be 40 mg/mL and a NOAEL was 
not determined. Non- GLP Study D -TR-02-2017 was conducted to evaluate the effects of intra -prostatic 
administration of NanoDoce. Male rats were administered a single dose of NanoDoce at 5 mg/mL (4  mg/kg), 10 
mg/mL (8 mg/kg), 20 mg/mL (16 mg/kg), or 40 mg/mL (32 mg/kg) as two 100 uL injections to each lobe of the prostate and the MTD was determined to be 40 mg/mL.  Two studies (non- GLP Study D -TR-06-2018 and GLP Study D -
TR-07-2019) evaluated  the effects of a single injec tion of NanoDoce into the kidney of male and female rats. 
NanoDoce suspensions  were delivered as four distinct injections into the renal cortex at the following doses: 0.625 
mg/kg (0.5 mg/mL), 2.5 mg/kg (2.0 mg/mL), 12.5 mg/kg (10 mg/mL), 25 mg/kg (20 mg/mL), and 50 mg/kg (40 mg/mL). Toxicity and toxicokinetic evaluations were performed for 8 (Study D -TR-06-2018) and 28 days (Study D -TR-
07-2019) after injection. The MTD at 8 days was determined to be 12.5 mg/kg and the NOAEL at 28 days was 
established to be  12.5 mg/kg with a corresponding AUC
0-672 of 1,440 ng*hr/mL.  
Clinical Summary:  
NanoDoce has not been administered to humans in a clinical trial to date. An extensive series of clinical studies were conducted to assess the safety of docetaxel formulated as Taxotere. 
In addition, intravesical administration of 
docetaxel in patients with bladder cancer has demonstrated safety and tolerability (McKiernan 2006; Laudano 2010; 
Barlow 2009a, Barlow 2009b, Barlow 2013) .  
NanOlogy provided NanoDoce drug product to an Investigator under Investigator -sponsored single patient expanded 
access. The patient was an [ADDRESS_518625].  
Relevant Literature:   
Although docetaxel is not approved for the  indication of urothelial carcinoma, it has been used off -label 
intravenously and intravesically for patients with bladder cancer.  
• Intravenous docetaxel is a widely accepted systemic treatment for advanced bladder cancer. Regulatory authorities worldwide have accepted docetaxel as a community standard and the National Comprehensive Cancer Network recommends docetaxel as second -line th erapy for metastatic bladder cancer ( Albany 2015).  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518626] Inc.  CONFIDENTIAL  Page 18 of 62 • Intravesical administration of docetaxel in patients with BCG -unresponsive  non-muscle invasive bladder 
cancer (NMIBC) has been reported. A Phase 1 trial investigated intravesical docetaxel in 18 subjects with 
recurrent high -grade Ta, T1 and Tis NMIBC  for whom BCG had failed ( McKiernan 2006 ). Barlow (2009) 
included the Phase 1 subjects in a retrospective analysis. Laudano (2010) followed -up by [CONTACT_411216] -
term results from the Phase 1 trial. Barlow (2013a) rolled the Phase 1 results and the retrospective review 
into a long -term analysis focused on survival outcomes, with an emphasis on maintenance treatment. 
Barlow (2009b ) conducted a study to evaluate the durability of response for patients with BCG -unresponsive  
NMIBC treated with intravesical docetaxel in a combined induction and maintenance regimen. In general, 
these studies report low grade local bladder adverse events (AE) including Grade 1 dysuria, Grade 1 
hematuria, Grade 2 hematuria, Grade 1 frequency, and Grade 1 urgency. Systemic toxicity was not reported. Initial complete response (CR) rates in these studies ranged from 22% to 76.9% ( with median follow -up 
ranging from  13 months to 48.3 months ). 
Importance of the study:  
Bladder cancer is the sixth most common cancer in the [LOCATION_002], with an estimated 79,[ADDRESS_518627] patients (approximately 75%) with bladde r cancer are 
diagnosed with disease confined to the mucosa or submucosa, classified as NMIBC ( Babjuk  2015). NMI BC is further 
stratified as low, intermediate or  high -risk. Most patients with high -risk NMIBC are treated with transurethral 
resection of the bl adder tumor (TURBT) followed by [CONTACT_411217]. The three therapi[INVESTIGATOR_411198] , bacillus Calmette -Guérin (BCG), Valrubicin, and thiotepa , are imperfect. Many 
patients do not respond to treatment, do not achieve a lasting response, and/or encounter serious treatment -related 
toxicities (TICE BCG Package Insert 2009,  Barlow 2013b, Babjuk 2017, Dinney 2013, Steinberg 2000, Hollister 1980).  
BCG is the current gold standard for intravesical therapy; however, 50% of patients treated with BCG experience recurrence ( Barlow 2013). Patients experiencing BCG failure have a 50% chance of disease progression ( Barlow 2013; 
McKiernan 20 06; Babjuk 2015 ). Ther efore, BCG failures represent the highest -risk subgroup of high- risk NMIBC. 
Approximately 25% of patients with bladder cancer present with a tumor invading the muscle layer of the bladder wall. Muscle invasive bladder cancer (MIBC)  is associated with a high rate of recurrence and poor overall prognosis 
despi[INVESTIGATOR_411199]. For decades, radical cystectomy has been the mainstay of treatment for muscle invasive bladder cancer. Despi[INVESTIGATOR_411200], surgery alone  does not result in optimal 
survival rates. Further, radical cystectomy is associated with considerable morbidity and mortality, as well as notable long- term complications and negative impacts on quality of life. There is increasing support for bladder spa ring 
approaches to muscle invasive bladder cancer treatment for those who cannot or will not undergo radical 
cystectomy (Park 2014, Smith 2013, Mak 2014 ). 
 
2.2 RATIONALE  
This Phase 1/[ADDRESS_518628] injection of NanoDoce to the tumor bed after TURBT may, in th e short term, kill residual 
tumor cells missed by [CONTACT_203839], in the long term, slowly release drug throughout the resection site over time to 
prevent recurrence.   
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518629] Inc.  CONFIDENTIAL  Page 19 of 62 2.3 POTENTIAL RISKS AND BENEFITS  
 
2.3.1  KNOWN  POTENTIAL RISKS  
There are no known potenti al risks from NanoDoce injection into the bladder wall of humans.   
Based on published studies of docetaxel, intravesical instillation toxicities include dysuria, hematuria, frequency, and 
urgency. Other adverse reactions  are facial and body flushing/erythema, limb cramps, rash, UTI, exhaustion, pain, 
incontinence, nocturia, general flu -like symptoms, decreased appetite, lightheadedness and premature docetaxel 
void .   
The risks associated with intravenous docetaxel are described in the Taxotere Package Insert. The most common 
adverse reactions across all Taxotere  indications are infections, neutropenia, anemia, febrile neutropenia, 
hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. Incidence 
varies depending on the indication.  
2.3.[ADDRESS_518630]  bladder wall injection or intravesical administration of NanoDoce  in 
humans.  
Published studies of docetaxel administered as a n intravesical instillation to subjects with BCG -unresponsive  NMIBC 
demonstrat ed an initial CR rate of between 22% and 76.9% , with median follow- up ranging from 13 months to 48.3 
months .  
3 OBJECTIVES AND  PURPOSE  
The primary objective of this study is to evaluate the safety and tolerability of NanoDoce  injected directly into the 
bladder wall and instilled intravesically .  
Secondary objectives are (a) to characterize the pharmacokinetics (PK) of docetaxel  when injected directly into the 
bladder wall in the presence of intravesical instillation ; and (b) to determine whether any of the NanoDoce  
concentrations  (0.75, 1.5, 2.5, or 3.75 mg/mL  administered by [CONTACT_17838]; 2.0 or 3.0 mg/mL administered by 
[CONTACT_137439] ) show signs of preliminary efficacy.   
4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF THE S TUDY DESIGN  
This open- label Phase 1/2 study  will enroll subjects  with pathological or cytological diagnosis of high -risk N MIBC or 
MIBC. Subjects will be stratified into two treatment groups, Group 1 ( NMIBC)  and Group 2 ( MIBC). The study drug 
will be delivered by [CONTACT_411218]. At Visit 2, all subjects will 
receive NanoDoce injected  into the index tumor resection site on the bladder wall, immediately following TURBT, 
followed by [CONTACT_411219]  (within [ADDRESS_518631] injection).  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518632] Inc.  CONFIDENTIAL  Page 20 of 62 Group 1 (NMIBC)  and Group 2 (MIBC) S ubset  
After a recovery period, Group 1 subjects will proceed to the 3- month Induction period . Subjects will be assessed for 
recovery (TURBT resection site healing) at Visit 4, at which point the Investigator will evaluate subject symptoms, 
pathology (if available), gross hematuria or urinalysis findings. If the Investigator determines that the subject has not recovered at Visit 4, evaluations will be re peated at least every [ADDRESS_518633] . Subjects will return at Visit 13 for an E nd of T reatment study 
visit. Plasma samples will be collected at Visit 2 ( prior to NanoDoce injection and at 1, 2, 6, and [ADDRESS_518634] -
injection ), at Visit 3, at Visit 4 ( prior to NanoDoce in travesical instillation  and at 1, 2, 6, and [ADDRESS_518635] - intravesical 
instillation), at Visits 5- [ADDRESS_518636] administration of NanoDoce . A PK plasma sample will 
be collected at the End of Treatment  visit. Institution patholog y data  will be collected for any resection, cystectomy 
or biopsy specimen (to include, but not limited to bladder resection, cystectomy or node tissue) at any time during 
the study or early withdrawal.  
 Progression, PFS and post -study bladder treatment or concomitant therapy will be collected at  [ADDRESS_518637] retained their bladders (non- cystectomy subjects). 
Group 2 ( MIBC)  
At the end of Visit 3 , Group 2 (M IBC) subjects may proceed to institutional standard of care (SOC) treatments and 
return for the  End of T reatment study visit 45 days (+/ - 5 days) after V isit 2. Alternately, a t Visit 3, a subset of 
subjects, as determined by [CONTACT_70440] I nvestigator, who are deemed ineligible for cystectomy and intolerant to 
existing standard of care chemotherapy or other treatment, may be offered the option to receive I nduction and 
Maintenance intravesical NanoDoce  (according to the regimen described for  Group 1)  (referred to hereafter as the 
“Group 2 Subset”) . The I nvestigator must determine and document there are no existing or available , standard of 
care  treatment options for the subject. Only at that time, will the Induction and Maintenance treatment be offered 
to the subject for consideration.    
Plasma samples will be collected at Visit 2 ( prior to NanoDoce inje ction, at  1, 2, 6, and [ADDRESS_518638] -injection ), Visit [ADDRESS_518639] retained their bladders (non- cystectomy subjects).  
Subjects who proceed to cystectomy will no longer have data collected after that point.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518640] Inc.  CONFIDENTIAL  Page 21 of 62 Dose Escalation: Groups [ADDRESS_518641] injection of NanoDoce 
concentrations  (0.75, 1.5, 2.5, or 3.75 mg/mL)  for Groups 1 and 2 ; dose escalation will also occur for the intravesical 
instillation of NanoDoce co ncentrations  (2.0 and 3.0 mg/mL) for Group s 1 and 2. See Section 6.1.7 Starting Dose and 
Dose Escalation for details . 
 
4.2 ENDPOINTS  
 
4.2.1 PRIMARY ENDPOINT  
The primary endpoint will be safety and tolerability as demonstrated by [CONTACT_117795], changes in laboratory assessments, 
physical exami nation findings and vital signs . 
4.2.2 SECONDARY ENDPOIN TS 
The secondary endpoints will be:  
• Concentration of docetaxel  in the systemic circulation post -injection in the presence of intravesical 
instillation (as determined by [CONTACT_411212]);  
• PFS defined as t umor recurrence  or disease progression at Visit 10 and Visit 13;  
• OS determined by [CONTACT_411220] t ime following NanoDoce injection . 
 
4.2.[ADDRESS_518642]: 
• Tumor -specific antigens (IHC);  
• Immunophenotypi[INVESTIGATOR_31081] T cells, B cells and monocytes.  
5 STUDY ENROLLMENT AND WITHD RAWAL  
 
5.1 PARTICIPANT  INCLUSION CRITERIA  
Patients who meet the following criteria will be considered eligible for participation in the study:  
• Signed informed consent;  
• Age ≥18 years;  
• Patients  with pathological or cytological diagnosis of:  
o High risk NMIBC1; 
 High grade (HG) T1;  
 Any recurrent, HG Ta;  
 HG Ta, >3 cm (or multifocal);  
 Any carcinoma  in situ  (CIS);  
 Any BCG failure2 in HG patient ; 
 Any variant histology;  
 Any lym phovascular invasion  (LVI) , to include any HG prostatic urethral involvement ; 
o MIBC; 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518643] Inc.  CONFIDENTIAL  Page 22 of 62 • Urothelial carcinoma  confirmed by b iopsy , urine cytology , computed tomography scan ( CT) or other 
institution -approved diagnostic methodology ; 
• All visible tumors removed during TURBT (as is reasonable, ensuring patient safety) ; 
• Performance Status (ECOG) 0 -2 at study entry;  
• Life expectancy of at least 6 months;  
• Adequate marrow, liver, and renal function; 
o ANC ≥ 1.5 x 109/L; 
o Hemoglobin ≥  9.5 grams/dL ; 
o Platelets ≥ 75 x 109/L; 
o Total bilirubin ≤ 1.5x institutional ULN ; 
o AST/ ALT ≤ 2.5x  institutional ULN ; 
o Creatinine ≤ 1.5x institutional ULN ; 
• Adequate method of birth control . 
 
1. As defined in the AUA/SUO Guideline (Chang 2016)  
2. BCG failure to be determined using the definition of BCG -unresponsive NMIBC as in “BCG -Unresponsive Nonmuscle Invasive 
Bladder Cancer: Developi[INVESTIGATOR_411201].” 
 a. BCG -unresponsive disease is defined as being at least one of the following:  
 i. Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papi[INVESTIGATOR_70283]/tumor invades the 
subepi[INVESTIGATOR_70321]) disease within 12 months of completion of adequate BCG therapy  
  ii. Recurrent high -grade Ta/T1 disease within [ADDRESS_518644] one of the following:  
i. At least five of six doses of an initial induction  course plus at least two of three doses of maintenance 
therapy;  
  ii. At least five of six doses of an initial induction course plus at least two of six doses of a second induction 
course.   
 
5.2 PARTICIPANT  EXCLUSION CRITERIA  
Patients who meet the followi ng criteria will be considered ineligible for participation in the study:  
• Metastatic  disease ; 
• Previous (within 12 months) or concurrent history of non- bladder  malignancy , except for non -melanoma 
skin cancer ; 
• Intravesical  therapy within 4 weeks prior to consent  (chemotherapy or immunotherapy including BCG 
administered directly into the bladder ); 
• Resection surface area greater than 8 cm2; 
• Upper tract and urethral disease within 18 months ; 
• Known hypersensitivity to any of the study drug  components or reconstitution components ; 
• Pregnant or breastfeeding ; 
• Participation in the treatment phase of another clinical trial within 3 months prior to consent;  
• Investigator’s opi[INVESTIGATOR_411202]’s probable noncompliance or inability to understand the trial and/or give 
adequate informed consent ; 
• Ongoing drug or alcohol abuse . 
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
Subjects  will be recruited at 5 study sites .  
It is not anticipated that any advertising will be required for recruiting to the study.   
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518645].   
At any time during the study, if there is tumor recurrence or disease pr ogression , decision to remove from study will 
be a consensus  between the I nvestigator, Medical Monitor and S tudy Director.  
The reason for withdrawal  will be documented in the source notes and in the Electronic Data Capture system (EDC ).  
Any potential or confirmed -related event , (clinical AE, laboratory abnormality, or other medical condition/situation) 
occurring, and/or DSMB determination  which may  be attributed to the withdrawal, must be documented and 
followed for the safety of the subject.   
Should the I nvestigator feel it to be in the best interest of the subject to be withdrawn from the study , the 
Investigator will immediately contact [CONTACT_411221]. 
5.4.[ADDRESS_518646]’s record.  
If a Group [ADDRESS_518647] in the cohort.   All data reported and collected will be included in the assessment of 
safety . 
5.5 PREMATURE TERMINATION OR SUSPENSION OF S TUDY  
This study may be temporarily suspended or prematurely terminate d, if there is sufficient reasonable cause. Written 
notification, documenting the reason for the study suspension or termination, will be provided by [CONTACT_411222]. If the study is prematurely terminated or suspended, the Investigator(s) will promptly in form the 
IRB(s) and will provide the reasons for the termination or suspension.  
Circumstances that may warrant termination include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subjects ; 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518648] Inc.  CONFIDENTIAL  Page 24 of 62 o Routine Medical Monitori ng determining a requirement for an ad hoc meeting of the DSMB, and/or 
routine DSMB reviews, will allow for termination of study based on unacceptable risk, which will 
consider all safety evaluations and DLTs.    
o Groups [ADDRESS_518649] two of six  subjects in that group experience DLT (as defined in Section 6 .1.7).  
o In the intravesical instillation dose escalation phase, the study may be terminated for a group if , at 
the lowest dose, at least two of three or two of six  subjects  in that group experience DLT (as 
defined in Section 6.1.7).  
• Insufficient complianc e with protocol requirements; 
• Data that are not sufficiently complete and/or evaluable;  
• Determination of futility.  
The s tudy may resume once concerns about safety, protocol compliance , and data quality are addressed and satisfy 
the Sponsor, IRB, and/or FDA . 
6 STUDY DRUG  
 
6.1 STUDY DRUG(S)  AND CONTROL DESCRIPTION  
 
6.1.1  ACQUISITION  
NanoDoce  is manufactured by [CONTACT_411223] , Inc. (Lawrence, KS)  and provided for use in this study.  Study drug  will not be 
shipped to the study site until all regulatory documentation has been provided to Sponsor  by [CONTACT_411224] , at which time the study drug  will be released by [CONTACT_411225].  Shipment will be 
via courier , temperature controlled at 59˚ to 86˚F (15˚ to 30˚C) just  prior to the site initiation  visit. Study drug  will be 
shipped to the institution  pharmacy where it will be stored according to the conditions required (see Section 6.1.3) . 
6.1.2  FORMULATION, APPEARANCE, PACKAGING, AND LABEL ING  
The NanoDoce Suspension kits (Clinical Supplies Kit)  provided to the study sites  will contain study drug  for all 
treatments and dosage groups in the study.  
Each  ‘Clinical Supplies Kit for NanoDoce Clinical Trials’ contain s one vial of NanoDoce and one vial of Sterile 
Reconstituti on Solution (1% Polysorbate 80 and 8% Ethanol in 0.9% Sodium Chloride for Injection, USP ). The 
NanoDoce 60 mL vial contains sterile nanoparticulate docetaxel (100 mg/vial), appearing as a white powder. When 
ready for use, the powder is suspended using the Sterile Reconstitution Solution provided in the kit.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518650] Inc.  CONFIDENTIAL  Page 25 of 62 The Clinical Supplies Kit will be labeled as:  
 
The NanoDoce vial will be labeled as:   
 
The reconstitution solution vial will be labelled as:  
 
6.1.[ADDRESS_518651]  be stored at  
the institution pharmacy , under limited access conditions and  temperature controlled at 59˚ to 86˚F (15˚ to 30˚C).  Clinical Supplies Kit for NanoDoce Clinical Trials  
Each kit contains:  
• 1 vial of NanoDoce (sterile nanoparticulate docetaxel)  
Powder for Suspension, 100 mg per vial                                                                                      
 
• 1 vial of Sterile Reconstitution Solution for  
NanoDoce Powder for Suspension, 5 mL per vial  
Caution: New Drug – Limited by [CONTACT_192321] – 
                                                              For single use only                                                                       #####  
 
NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension, 100 mg vial  
Lot.: ________  
Prior to  reconstitution, Store at 59 ° to 86°F (15° to 30°C).  
Reconstitute according to the Instruction Sheet and the procedure in the clinical protocol.  
After reconstitution, store the suspension per Instruction Sheet.  
Caution: New Drug – Limited by [CONTACT_411226]: CritiTech, Inc., [ADDRESS_518652], Lawrence, KS [ZIP_CODE]  
Manufactured for: US Biotest, Inc., [ADDRESS_518653], San Luis Obispo, CA [ZIP_CODE]      XXXXX  
Sterile Reconstitution Solution for NanoDoce (sterile nanoparticulate docetaxel) Powder for 
Suspension  
Lot No.: ________  
Contains: 5 mL of 1% Polysorbate 80 (NF) and 8% Ethanol (USP) in 0.9% Sodium Chloride for Injection (USP) per vial  
Prior to use, store at 59 ° to 86°F (15° to 30°C).  
For single use only  
Caution: New Drug – Limited by [CONTACT_411227]: The University of Iowa Pharmaceuticals, [ADDRESS_518654].,  
                                  Iowa City, IA [ZIP_CODE]  
Manufactured for: US Biotest, Inc., [ADDRESS_518655],                                    San Luis Obispo, CA [ZIP_CODE]                                                                                    XXXXXX  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518656] Inc.  CONFIDENTIAL  Page 26 of 62 Reconstitution will be performed in the p harmacy. Once the NanoDoce  has been reconstituted, it will  be delivered 
for injection or instillation at the desired location (treatment area, clinic or operating room ). If the reconstituted drug  
is not delivered immediately , the syringe may be stored according to pharmacy manual i nstructions  until delivery . 
Each vial and each syringe must be labelled according to institution requirements  as well with the subject study 
number . 
6.1.4  PREPARATION  
A prescription (drug order) will be provided to the pharmacy for each subject detailing the  subject study number , the 
assigned cohort dose , and  the date and time required for administration, as well as any institution -required 
instructions for study drug identification . The drug order should be provided to the Pharmacy at least 24 hours prior 
to administration time , or per institution requirements . The site will provide 0.9% Sodium Chloride for Injection, USP , 
a sterile syringe with a sterile 18- gauge needle (or larger bore) for sterile injectable drug preparation and a suitable 
sterile container to prepare secondary dilutions, as necessary.   
Direct Injection: Once the drug has been reconstituted to the required cohort -assigned dose for injection (3.0, 6.0, 
10.0 or 15.0 mg), the maximum injection volume of 4.0  mL will be withdrawn  from the vial into a syringe.  
Intravesical  Instillation: Once the drug has been reconstituted to 2.0 mg/mL or 3.0 mg/mL, the appropriate volume of 
the NanoDoce suspension will be withdrawn from the vial and transferred to an appropriate delivery receptacle for 
instillation . 
Each Clinical Supplies Kit, including entire contents, is for a single -subject use only. Reconstitution will be performed 
by [CONTACT_3449]- delegated pharmacy st aff and the final study drug  concentration (whether for direct injection or intravesical 
instillation) will be delivered by [CONTACT_411228] , or designee. Sponsor will provide s eparate written 
instructions in the pharmacy manual and an inst ructional video will be provided by [CONTACT_411229].   
NanoDoce  must be administered no more than 4 hours after the initial reconstitution . 
6.1.5  DOSING AND ADMINISTRATION  
Groups 1 and 2: Direct Injection  
NanoDoce will not  be injected if there is any evidence of bladder perforation (visible fat or bowel). Confirmed or 
suspected perforation  prior to NanoDoce injection  will terminate participation in the study and the subject will be 
conside red a Screen Fail . If perforation  is not detected during the resection and the subject proceeds to NanoDoce 
injection and/or instillation,  the subject will terminate participation in the study at the time the perforation is 
detected  and proceed to the End of Treatment and safety visit, [ADDRESS_518657] resection site ( should not exceed 
8.0 cm2) if multiple resections are performed. If multiple resections are performed, only the index tumor resection 
site will receive NanoDoce injections.  
Adjustable  tip-length cystoscopy  needles are to be used for injection into the resected bladder wall . The needle tip to 
be adjusted  to 2 mm (p er manufacturer  recommendation ) for injections in the dome area of the bladder and 3 – 4 
mm for injections in the side area of the bladder . A total volume of 4.0 mL of NanoDoce will be injected in 0.5 mL 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518658] Inc.  CONFIDENTIAL  Page 27 of 62 increments , approximately 1 cm apart, with up to 8 injections  into the index tumor resection site. Injections will be  
performed in a tangential approach (grid -like pattern to cover the resection site) so the needle tip is viewable under 
direct visualization by [CONTACT_411230].  The investigator will inject up to 5 mm outside of the resec tion margin.  
The total dose administered will not exceed the assigned cohort dose  of 3.0 (0.75 mg/mL), 6.0 (1.5 mg/mL), 10.0 (2.5 
mg/mL), or 15.0 (3.75 mg/mL) mg.  
Groups 1 and 2 : Visit [ADDRESS_518659] injection ( <2 hours). NanoDoce will be 
instilled intravesically in the bladder for a maximum of 30 minutes (+/ - 5 min).   
The total dose administered will not exceed the assigned cohort dose  50 mg in 25 mL of saline  for a final 
concentration of 2.0 mg/mL or 75 mg in 25 mL of saline  for a final concentration of 3.0 mg/mL.      
The subject will be in supi[INVESTIGATOR_2547]. Local anesthetic  gel is allowed for catheter placement. The urinary catheter 
will be inserted into the bladder using sterile technique. Isotonic saline or sterile water is the only distending medium 
which will be allowed in this study.  Following intravesical instillation, the subject will be asked to change position 
every  15 minutes to ensure uniform coating of study medication to the bladder wall. On Visit 2, a t the end of the 30-
minute dwell time, the instillate will be drained by [CONTACT_411231]; the catheter will be 
removed, and the drained fluid and catheter will be disposed of, per institution  requirements.  
Group 1  and Group 2 S ubset : Induction and Maintenance Intravesical Instillation   
If Induction and Maintenance intravesical instillations are  administered in a hospi[INVESTIGATOR_6885], the instillate will be 
drained by [CONTACT_411231]; the catheter will be removed, and the drained fluid and catheter 
will be disposed of, per institution requirement . If the subject is not cathete rized, the subject will void in the toilet . 
Total instillate retention time will be recorded for study purposes.  
Visits 4-9 Induction:   NanoDoce will be instilled in the bladder once/week for 6 weeks  for a maximum of 120 minutes 
(+/- 10 min) .  
Visits 10- 12 Maintenance :  NanoDoce will be instilled in the bladder once/week for 3 weeks  for a maximum of 120 
minutes (+/ - 10 min) .  
 
6.1. 6 ROUTE OF  ADMINISTRATION  
NanoDoce will be administered by [CONTACT_411232]: as a direct injection to the bladder wall and as intravesical 
instillation (s) in the bladder . 
6.1.[ADDRESS_518660] injection of NanoDoce concentrations  (0.75, 1.5, 2.5, or 3.75 mg/mL)  for Group s 1 and 2.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518661] Inc.  CONFIDENTIAL  Page 28 of 62 Table 1: NanoDoce Direct Injection Dose-Escalat ion 
Cohort  NanoDoce Suspension  
Concentration  Maximum # of 
Injections  Total NanoDoce Administered  
‘Not to Exceed’  
1 0.75 mg/mL  8 3.0 mg  
2 1.5 mg/mL  8 6.0 mg  
3 2.5 mg/mL  8 10.0 mg  
4 3.75 mg/mL  [ADDRESS_518662] concentration  
(0.75 mg/mL ) (Table 1 ). Cohorts will enroll separately for Groups [ADDRESS_518663] a planned minimum 
of three subjects  for Group 1 and three subjects  for G roup 2 . Escalation to the next cohort  for Group 2 will proceed  
following review of Group 1 data by [CONTACT_4318]. All clinical data from subjects in each cohort, including all DLTs 
described in this section  and excluding PK, will be reviewed and evaluated by [CONTACT_3433] e Medical Monitor and DSMB ( based 
on the DSMB c harter ) on an ongoing basis, in addition to at Visits 4, 6 and 9, to determine if the dose received is 
considered safe and tolerable, and to determine if dose escalation may occur.   
If the DSMB determin es cohort 1 (0.75 mg/mL ) is safe (no DLT), escalation to the next dose level , cohort 2 ( 1.5 
mg/mL ), will occur. If >[ADDRESS_518664] three subjects , the study will stop. If 1 DLT occurs at cohort  1, three 
additional subjects will be added to cohort  1. If >1 DLT occurs in the additional three subjects , the study will stop. If 
no additional DLT  occurs in the additional three subjects , the study will e scalat e to the next dose level , cohort 2 ( 1.5 
mg/mL ).  
Three subjects  will be dosed at cohort  2 (1.5 mg/mL ). If the DSMB determin es cohort 2 is safe (no DLT), e scalation to 
the next dose level , coho rt 3 (2.5 mg/mL ), will occur. If >[ADDRESS_518665] three cohort  2 subjects , the study 
will return to the previous (lower) dose , cohort 1 ( 0.75 mg/mL ), and proceed to dose confirmation. If 1 DLT occurs at 
cohort 2, three additional subjects will be  added to cohort  2. If > 1 DLT  occurs in the three additional cohort 2 
subjects , the study will return to the previous (lower) dose , cohort 1 ( 0.75 mg/mL ), and proceed to dose 
confirmation. If no additional DLT  occurs in the additional three subjects , the study will e scalat e to the next dose 
level , cohort 3 ( 2.5 mg/mL).  
Three subjects  will be dosed at cohort  3 (2.5 mg/mL ). If t he DSMB determin es cohort 3 is safe (no DLT), e scalation to 
the next dose level , coho rt 4 (3.75 mg/mL ), will occur. If > [ADDRESS_518666] three cohort  3 subjects , the study 
will return to the previous (lower) dose , cohort 2 (1.5 mg/mL ), and proceed to dose confirmation . If 1 DLT occurs at 
cohort 3, three additional subjects will be added to cohort 3. If > 1 DLT  occurs in the three additional cohort 3 
subjects , the study will return to the previous (lower) dose , cohort 2 (1.5 mg/mL ), and proceed to dose confirmation. 
If no additional DLT  occurs in the  additional three subjects , the study will e scalat e to the next dose level , cohort 4 
(3.75 mg/mL ).  
Three subjects  will be dosed at cohort  4 (3.75 mg/mL ). If the DSMB determin es cohort 4 is safe (no DLT), dose 
confirmation at cohort 4  (3.75 mg/mL) will occur. If > [ADDRESS_518667] three cohort  4 subjects , the study will 
return to the previous (lower) dose , cohort 3 (2.5 mg/mL ), and proceed to dose confirmation . If 1 DLT occurs at 
cohort 4, three additional subjects will be added to cohort 4. If > 1 DLT  occurs in the three additional cohort 4 
subjects , the study will return to the previous (lower) dose , cohort 3 (2.5 mg/mL ), and proceed to dose confirmation. 
If no additional DLT  occurs in the additional three subjects, the study will complete enrollment at c ohort  4 (3.75 
mg/mL ) in dose confirmation.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518668] cohort experience DLT, the previo us dose will  be taken into the dose c onfirmation 
phase.   
Once the dose deemed appropriate for further evaluation has been determined by [CONTACT_4318], additional subjects will be enrolled to provide up to a total of up to 9 subjects  dosed at that dose level.  
Intravesical Instillation  
The study will also dose escalate Group s 1 and 2 for the intravesical instillation of NanoDoce concentrations  (2.0 and 
3.0 mg/mL) . In the intravesical instillation dose escalation phase, all s ubjects in Group [ADDRESS_518669] 
concentration of 2.0 mg/mL for the Visit 2 instillation. If the dose is well- tolerated, Group 1 subjects will continue to 
receive 2.0 mg/mL  through V isit 6, then escalate to 3.0 mg/mL intravesical instillat ions for the subsequent Induction 
and Maintenance intravesical instillations following ongoing data review by [CONTACT_120782] .  
Group [ADDRESS_518670] concentration of 2.0 mg/mL for the Visit [ADDRESS_518671] 
injection doses. If the dose is well -tolerated  for the Group 1 subjects ( following ongoing data review by [CONTACT_411233] ) Group 2 and Group 2 subset  subjects will escalate to 3.0 mg/mL intravesical instillations for 
the dose confirmation phase  of the study.   
Escalation to 3.0 mg/mL  in each group will proceed , independent of the other group. If no subjects in cohort 1  at 2.0 
mg/mL experience a DLT, the intravesical dose wi ll escalate to 3.0 mg/mL for that group as described below. If two or 
more subjects in cohort 1  experience a DLT at 2.0 mg/mL, then the study will stop. If one of the three subjects in 
cohort 1  experiences a DLT at 2.0 mg/mL, then an additional three subje cts will be enrolled to cohort 1 at 2.0 mg/mL . 
If, in the additional three subjects at 2.0 mg/mL, no subjects experience a DLT, then the dose will remain at 2.0 mg/mL as described below.  If >1 DLT  occurs in the additional three subjects , the study will sto p. 
Definition of DLT  
Included in the DSMB’s review of AEs and general study data pertaining to safety (laboratory results , vital signs , 
physical examination findings ) there will be rules for non -escalation . Any AE that is considered related or probably 
related to NanoDoce  is potentially a DLT. The definition of a DLT will be determined  by [CONTACT_411234]. DLTs will, in addition,  include the following:  
• Procedure -related events that require hospi[INVESTIGATOR_411203] -related 
events that require medical intervention ; 
• All Grade 3 -4 AE which are possibly related to study drug will be considered DLT except : 
o Grade [ADDRESS_518672] not received optimal anti -emetic or anti -diarrhea prophylaxis;  
o Grade 3 fatigue less than 5 days ; 
o Grade 3 laboratory abnormalities that are not clinically significant and return to normal (with or 
without interventio n) within 48 hours ; 
• Grade 3 thrombocytopenia with clinically significant hemorrhage;  
• Grade [ADDRESS_518673] 3 weeks;  
• Any life -threatening event (unless there is a clear alternative explanation that the ev ent is not related to the 
procedure or the investigational product itself).  
 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518674] Inc.  CONFIDENTIAL  Page 30 of 62 6.1. 8 DOSE  ADJUSTMENTS/MODIFICATIONS/DELAYS  
Group 1  and Group 2 S ubset  
At any time during Induction or Maintenance, intravesical instillations will be withheld in weekly increments in the 
event of Grade 2 thrombocytopenia, anemia, neutropenia, hematuria (visible gross hematuria) or laboratory -
confirmed urinary tract infections until the infection is resolved. The hematuria and abnormal CBC values must 
resolve to a maximum of Grade 1.   
Group [ADDRESS_518675]; therefore,  there will be no dose 
adjustment or modifi cation .                                                                                                                                                                          
6.1. [ADDRESS_518676] up to 33 weeks. 
Survival data will be collected up to 12 months ; clinic visits will not be required . 
Group [ADDRESS_518677] up to 64 days.  Survival data will be collected up to 12 
months; clinic visits will not be required.  
6.1.1 0 TRACKING OF DOSE  
Not applicable.  
6.1.1 1 DEVICE SPECIFIC CONSIDERATIONS  
Not applicable.  
6.2 STUDY DRUG ACCOUNTABILITY PROC EDURES  
The Investigator will maintain adequate records showing the receipt, dispensing, return, or other disposition of the 
investigational drug, including the date, quantity, lot number , and identification of subjects (number, initials  as 
allowed ) receiv ing stud y medication.   
Accountability will be conducted by [CONTACT_411235] , the individual 
NanoDoce vials, and the sterile reconstitution solution .  No used vials will be kept for accountability purposes, they 
will be disposed of according to the institution destruction procedures .  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518678] Inc.  CONFIDENTIAL  Page 31 of 62 If Investigator determines that the full volume of NanoDoce  cannot be administered, the Investigator will document 
the amount of NanoDoce  injected  or instilled  and the volume remaining  in the  vial, in the source  document  and in 
the EDC . 
Under no circumstances will the Investigator supply clinical material to other Investigators or clinicians or allow the 
supplies to be used other than as directed by [CONTACT_411236] S ponsor.  
7 STUDY PROCEDURES AND  SCHEDULE  
 
7.1 STUDY PROCEDURES/EVA LUATIONS   
 
7.1.1  STUDY SPECIFIC PROCEDURES   
The following procedures and evaluations will be done as part of this study.  
• Complete medical history and demographics  collection and documentation ; 
• Concomitant prescription and non- prescription medication  collection and documentation ; 
• Urothelial carcinoma  diagnosis and treatment documentation; 
• Comprehensive physical examination, including ECOG ; vital signs , body weight a nd height;  
o Respi[INVESTIGATOR_411204]; this will not be a deviation. For 
those institutions providing the measurement, the data will be collected  as described in Section 
7.3.  
• 12-lead ECG; 
• PK sampl ing; 
• Routine clinical laboratory s ampl ing; 
• Diagnostic biopsy and/or imaging with CT scan s including, but not limited to histological reports to include 
lymph node data. A copy of the pathology report confirming the diagnosis must be filed in the subject’s study record;  
• Bladder tissue slides for immunohistochemistry staining collected during the course of the trial;  
• NanoDoce  injection of the  index tumor resection site post -TURBT;  
• Intravesical NanoDoce  instillation (s); 
• Subject diary complet ion. 
7.1.[ADDRESS_518679] care routinely provide d (such as pain relief, additional clinic visits , etc.).  
Group [ADDRESS_518680] injection and intravesical instilla tion, subjects may proceed to SOC .  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518681] Inc.  CONFIDENTIAL  Page 32 of 62 7.2 LABORATORY PROCEDURES/EVALUATIONS  
 
7.2.1  CLINICAL LABORATORY EVALUATIONS  
Clinical laboratory assessments will be conducted at the local CLIA certified laboratory routinely used by [CONTACT_3786].  
Laboratory Assess ments include : 
• Biochemistry analysis  to be performed at V isits 1, 4, 10 and End of Treatment for Group 1 and V isits 1 and 
End of Treatment for Group 2 to include : Sodium, potassium, chloride, carbon dioxide (CO 2), calcium, 
phosphorus, glucose, blood urea nitrogen (BUN), creatinine, serum lipase, serum amylase, alkaline 
phosphatase  (ALP), total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate 
dehydrogenase (LDH), total protein, albumin, triglycerides, cholesterol, uric acid and calculated creatinine clearance;   
• Complete blood count (CBC) at each visit (except V isit 3 for Group 1 subjects ) to include: Red blood cells 
(RBC), white blood cells (WBC) including complete differential, hemoglobin (Hgb), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet (Plt)  and reticulocyte count ; 
• Urinalysis  at each visit (except V isit 3 for Group 1 subjects ) including specific gravity, hydrogen ion 
concentration (pH), RBC, WBC, protein, and glucose;  
• Activated partial thromboplastin time (aPTT) and prothrombin time (PT)  to be performed at V isits 1, 4, 10 
and End of Treatment for Group 1 and Group 2 subset and at Visits 1 and End of Treatment for Group 2 ; 
• Fibrinogen assay  to be performed at Visits 1, 4, 10 and End of Treatment for Group 1 and Group 2 subset 
and at V isits 1 and End of Treatment for Group 2 .  
Blood for routine laboratory assessments will be collected and processed per institution requirements and 
guidelines.  
7.2.2  OTHER ASSAYS O R PROCEDURES   
[IP_ADDRESS]  PATHOLOGY EV ALUATIONS  
Any t issue sample collected during  the study  will be processed per institution pathology standards , to include but not 
limited  to: pathologist review of tissue blocks and histological quality check; pathologist clinical data review, 
including stage confirmation; and H&E staining .  
Additionally , once study eligibility is confirmed at Visit 2 (see Section 7.3.2) , biopsy sample s collected during the 
study (starting with initial TURBT)  will be mounted on slides and shipped to a central laboratory for 
immunohistochemistry  (IHC) research . Shipment process for the IHC slides to NeoGenomics  will be described in the 
IHC Laboratory manual . 
7.2. 2.2 PHARMACOKINETICS 
Plasma samples will be collected to characterize the PK of docetaxel. Visit 2 (Day 1) PK samples will be collected as of ‘stop time’ of the last injection; Visit 4 (Day 1) PK samples will be collected as of ‘stop time’ of instillation. 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518682] Inc.  CONFIDENTIAL  Page 33 of 62 Group 1  and Group 2 subset  
Plasma samples will be collected at Visit 2 ( prior to NanoDoce injection and at 1, 2, 6, and [ADDRESS_518683] -injection ), at 
Visit 3, a t Visit 4 (prior to NanoDoce in travesical instillation  and at 1, 2, 6, and [ADDRESS_518684] - intravesical instillation), 
at Visits 5- 12 prior to  NanoDoce  intravesical  instillation, and at the End of Treatment  visit. Allowable visit 2 and visit 4 
windows will be: 10- minute s for hours [ADDRESS_518685].    
Group 2  
Plasma samples will be collected at Visit 2 ( prior to NanoDoce injection and at 1, 2, 6, and [ADDRESS_518686] -injection ), 
Visit 3,  and at the End of Treatment visit . Allowable Visit 2 windows will be: 10- minute s for hours [ADDRESS_518687].   
7.2.2. 2.1 PK SPECIMEN PREPARATION , HANDLING, AND STOR AGE  
PK samples will be drawn at the specified time for each v isit, processed  and stored frozen on -site until instructed to 
ship by [CONTACT_456] , at which time they will be batch -shipped to Covance Laboratories  (Madison, WI) for analysis  of 
docetaxel . Procedures for storage processing will be described in the PK Laboratory Manual provided at study 
initiation.  
7.2.[ADDRESS_518688] UDY SCHEDULE  
 
7.3.1  SCREENING  (VISIT 1)  
Groups 1 and 2 will complete the Screening visit (Visit 1). Assessments, visits, and other assays performed prior to  
consent to the study for NanoDoce  injection , will be performed according to the institution SOC  and are not 
considered part of this study. The following procedures and assessments must be completed, documented and 
reviewed by [CONTACT_343891] s creening period, within 30 days prior to NanoDoce  Visit 2 injection , unless 
otherwise indicated : 
• Written informed consent including comprehensive discussion of the study schedule, procedures and 
subject protocol requirements;  
• Complete medical history, including review of previous medical records  and demographics;  
• Review and documentation of urothelial carcinoma  diagnosis ( diagnostic biopsy and/or imaging, 
cystoscopy and or cytology ) obtained within three months of consent. A copy of the pathology report 
confirming the diagnosis must be filed in the subject’s study record;  
• Review and documentation of p reviou s treatments including surgical, chemotherap y and immunologic 
records ;  
• Review and documentation of all concomitant prescription and non- prescription medications;  
• Comprehensive physical examination  within the 14 days prior to Visit 2; 
• ECOG Performan ce Status  (Appendix A)  within the 14 days prior to Visit 2; 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518689] Inc.  CONFIDENTIAL  Page 34 of 62 • 12-lead ECG; 
• Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_7146] ) within the 14 days prior to Visit 
2; 
• Body weight and height;  
• Pregnancy test (urine) for females of child -bearing potential;  
• Sample collection and processing for clinical laboratory assessments  (see Section 7.2.1)  
 
7.3.2  TRANS URETHRAL RESECTION OF B LADDER TUMOR (VISIT 2)  
Groups 1 and 2 will complete Visit 2.  
• Medical history confirmation ( AE occurring prior to NanoDoce  injection will be considered history ); 
• Comprehensive physical examination  (if not completed within the 14 days prior to Visit 2) ; 
• ECOG Performance Status assessment  (if not completed within the 14 days prior to Visit 2) ;  
• Final review of inclusion and exclusion criteria  and determination of eligibility prior to NanoDoce 
injection ; 
• TURBT ; 
o Confirmation of non -bladder perforation during  TURBT must be documented and filed in the 
subject’s study record;  
o Trans -urethral resection surface area to be recorded (< 8 cm2); 
o If subject does not qualify or bladder perforation is confirmed, subject will not  proceed to 
NanoDoce  injection and will be considered a Screen  Fail; 
• If continuation to NanoDoce  injection is confirmed, the bladder resection tissue sample collected will be 
processed  according to Section [IP_ADDRESS]; 
 
7.3. 3 NANODOCE TREATMENT - INJECTION & INTRAVES ICAL INSTILLATION  (VISIT 2  
CONTINUED ) 
Groups 1 and 2 will complete Visit 2.  
• Baseline PK sample will be drawn prior to NanoDoce injection ; 
o May be collected at any time during screening prior to TURBT procedure ; 
• Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697]) will be monitored and collected prior to 
NanoDoce injection ; 
o Vital signs will be monitored and collected per SOC; it is expected during surgery and recovery, 
continuous vitals monitoring will be conducted ; 
• NanoDoce injection  of the resected bladder tumor;   
o Start time of first injection and stop time of last injection will be recorded;  
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_697]) will be monitored and collected post  NanoDoce  
injection ;  
• NanoDoce i ntravesic al instillation ;  
o Start time of instillation and time at end of void will be recorded;  
• Vital signs  (blood pressure, heart rate, respi[INVESTIGATOR_697]) will be monitored and collected post NanoDoce  
intravesical instillat e (catheter removed and instillate voided) ; 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518690] Inc.  CONFIDENTIAL  Page 35 of 62 • Collection of AE ( start time of first  NanoDoce  injection ) will be documented separately as treatment -
emergent  adverse events  (TEAE) ; 
• Collection of concomitant medication;  
• PK samples will be drawn at 1, 2, [ADDRESS_518691] NanoDoce injection stop time ; 
• Subject will be provided a diary to record AE and concomitant medications until the next study v isit. 
 
7.3.4  VISIT 3  
Group s 1 and 2  
• One PK sample will be drawn.  
Group 2  
• Directed physical exam;  
• CBC and urinalysis s ample collection   
o PK samples can be collected and processed at the same time as CBC samples.  
• AE review;  
• Concomitant medication review;  
• Review of eligible treatment options;  
• The Investigator will document all treatment options following review of subject records and institution 
standard of care protocols, and i f it is determined  that the  subject is not a candidate for cystectomy or 
standard of care treatment, the Investigator will discuss with the subject the option of participating in the 
Group 2 S ubset  for Visits 4- 9 Induction and Visits 10- 12 Maintenance instillation s, as an alternative choice .  
 
Group 2 S ubset   
• Written informed consent including comprehensive discussion of the study schedule, procedures and 
subject protocol requirements  may be conducted at any time  from Visit 3 up to Visit 4 (prior to the first 
Induction instillation).  
7.3. 5 I NDUCTION PERIOD (VISITS 4 – 9) 
 
Only Group 1 and Group 2 subset subjects will complete the Induction Period (Visits 4-9 ). Subjects will be assessed 
for recovery (TURBT resection site healing) at Visit 4, at which point the Investigator will evaluate subject symptoms, pathology (if available),  and gross hematuria or urinalysis findings.  If the Investigator determines that the s ubject has 
not recovered at Visit 4, evaluations will be repeated at least every [ADDRESS_518692] has recovered , at which 
time intravesical NanoDoce can be administered.  
At any time during the I nduction Period , if intravesical instillation is  delayed , the next instillation visit s will be 
recalculated based on the new/rescheduled instillation date and per visit timelines and windows ( see Schedule of 
Events: Table 2b).  
The 3-month  Induction perio d will consist of [ADDRESS_518693] . The following procedures will be performed:  
• Vital signs ; 
• Directed physical exam;  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518694] Inc.  CONFIDENTIAL  Page 36 of 62 • Sample collection and processing for clinical laboratory assessments (Section 7.2.1);  
o Non -clinically signif icant CBC and urinalysis must be confirmed prior to each intravesical 
instillation to rule out infection or DLT. A 48- hour window is allowed for sample collection and 
processing to ensure results are available prior to the intravesical instillation.  
o If ap plicable, chemistry, fibrinogen, a PTT, PT and PK samples can be collected and processed at 
the same time as CBC sample s.  
o Visit 4 only:  
 Chemistry, fibrinogen, aPTT and PT;  
 PK samples will be drawn prior to  NanoDoce  instillation  and at 1, 2, 6, and [ADDRESS_518695] op time; 
o Visits 5-9: 
 PK samples will be drawn  prior to NanoDoce  instillation;  
• Intravesical NanoDoce  instillation (Section 6.1.5);  
• AE review;  
• Concomitant medication review;  
• In addition to the Visit 4 cystoscopy and cytology, at any time during the induction period, the I nvestigator 
may perform cytology, cystoscopy or biopsy ( for positive or suspi[INVESTIGATOR_411195]);  
o Any tissue sample collected will be processed according to  Section [IP_ADDRESS] ; 
• Subject diary will be reviewed to confirm it is adequately completed. The subject will be questioned 
regarding discrepancies, missing entries and errors. Any discrepancy will be documented in the subject source documents by a delegated staff; and a new diary to be provided to the subject to record instillate void time and for daily completion to record adverse events and concomitant medications.  
 
7.3. 6 MAINTENANCE PERIOD (VISITS 10 – 12) 
Only Group 1 and Group 2 subset subjects will complete the M aintenance Period (Visits 10- 12). Visit [ADDRESS_518696] day of the 3- month Induction period. If biopsy is indicated, maintenance therapy 
with NanoDoce is to be withheld until the histopathology results are available. NanoDoce intravesical instillation may 
be delayed up to 3 weeks.   
At any time during the Maintenance Period , if intravesical instillation is delayed , the next instillation visit will be 
recalculated  based on the new/rescheduled maintenance instillation date and per visit timelines and windows (See 
schedule of Events: Table 2b).  
At Visit 10, subjects will proceed to a 3- month  Maintenan ce period consisting of  three NanoDoce intravesical 
instillations  to be administered once weekly , in the first three weeks .  
 
The following procedures will be performed at Visits 10 - 12: 
• Directed physical exam may be performed;  
• ECOG – Visit 10 only;  
• Vital signs ; 
• Sample collection and processing for clinical laboratory assessments (Section 7.2.1);  
o Chemistry, aPTT and PT at Visit [ADDRESS_518697] be confirmed prior to  each  intravesical 
instillation to rule out infection or DLT ;  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518698] Inc.  CONFIDENTIAL  Page 37 of 62 o A 48- hour window is allowed for sample collection and processing to ensure results are 
available prior to the intravesical instillation.  
o Chemistry, fibrinogen, aPTT, PT and PK samples can be collected and processed at the same 
time as CBC samples.  
• Intravesical NanoDoce  instillation s (Section 6.1.5);  
• PK samples will be drawn pre - NanoDoce  instillation ; 
• In addition to the Visit 10 cystoscopy and cytology, a t any time during the maintenance period , the 
Investigator may perform cytology, cystoscopy or biopsy ( for positive or suspi[INVESTIGATOR_411205]);  
o Any tissue sample collected will be processed according to Section [IP_ADDRESS] ;  
• AE review;  
• Concomitant medication review;  
• Subject diary will be reviewed to confirm it is adequately completed. The subject will be questioned 
regarding discrepancies, missing entries and errors. Any discrepancy will be documented in the subject source documents by a delegated staff; and a new diary to be provided to the subject to record instillate void time and for daily completion to record adverse events and concomitant medications.  
 
7.3. 7 END OF T REATMENT  
The End of Treatment  visit (Visit 13) will be conducted after a subject completes the Day [ADDRESS_518699] treatment to assess ongoing or new AEs. 
At the visit, the following procedures will be performed:  
• Comprehensive physical exam; 
• ECOG;  
• Vital signs ; 
• 12-lead ECG; 
• Clinical laboratory sample collection (Section 7.2.1);  
• PK Sample collection  (one sample collection only ); 
• Cystoscopy, urine cytology;  
• Biopsy;  
o Performed for positive or suspi[INVESTIGATOR_411195];  
o Any tissue sample collected will be processed according to Section [IP_ADDRESS] ; 
• AE collection;  
• Concomitant medication;  
• Subject diary will be reviewed to confirm it is adequately completed. The subject will be questioned regarding 
discrepancies, missing entries and errors. Any discrepancy will be documented in the subject source documents by a delegated staff.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518700] study drug is administered (injection and/ or instillation). 
The visit can be combined with t he End of Treatment  visit if both are conducted [ADDRESS_518701] study visit 
will be completed , in addition to a visit for safety  (see 7.3. 8), so they are aware of expectations.  
7.3.10 SURVIVAL/PROGRESSION  FOLLOW -UP  
   
Data will be collected for all subjects at 6 (Group 2 only), 9 and 12 months after Visit 4 to include progression, PFS and OS. Data will include concomitant therapy for bladder cancer (radiation, chemotherapy, immunotherapy and surgical intervention).  An additional subject visit will not be required as data will be collected by [CONTACT_14716]. In cases where the subject has moved or lives in another city, data will be requested from the treating physician/institution. If the subject is no longer being follow ed by a treating physician/institution, a phone call may 
be conducted to determine survival and to collect the last post -study concomitant treatment data. This data will be 
collected for information only and will not be used to support a study endpoint.  
7.3.11 UNSCHEDULED VISITS  
Any unscheduled visits will be documented in the source  documents , and any assessments and/or evaluations 
performed will be noted and reviewed.  The subject will undergo any evaluations as determined necessary by [CONTACT_3786].  All evaluations or procedures performed at the unscheduled visit, will be entered in the EDC.    
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518702], Inc.  CONFIDENTIAL  Page 39 of 62 7.3.10 S CHEDULE OF E VENTS TABLE  
 
Table 2 a: Group 1 (NMIBC)  and Group 2 Subset Schedule of Events  
Procedure  Screening  Treatment   Induction  
Days      
(-30 - 0) Visit 2  Visit 3 Visit 4 1, 2 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 
Day 1  Day 15 
(+/- 1 day)  Day 1  
Week 1  
(> 4 weeks)  Day 8  
Week 2  
(+/-2 days)  Day 15  
Week 3  
(+/-2 days)  Day 21 
Week 4  
(+/-2 days)  Day 28  
Week 5  
(+/-2 days)  Day 35  
Week 6  
(+/-2 days)  
Informed Consent  X         
Medical and Surgical History3 X         
Demographics  X         
Physical Examination4 X X5  X X X X X X 
ECOG  X X5        
12-Lead ECG  X         
Vital Signs6 X X  X X X X X X 
Height and Weight  X         
Pharmacokinetic Collection   X7 X7 X7 X8 X8 X8 X8 X8 
Laboratory Tests9 X   X X X X X X 
NanoDoce Direct Injection   X        
NanoDoce  Intravesical 
Instillation  X  X X X X X X 
TURBT10  X        
Cystoscopy 10, 11 X   X      
Cytology 10, 11 X   X      
Biopsy,10, 11 X   X11      
Immunohistochemistry12  X  X X X X X X 
Diary Distribution   X  X X X X X X 
Diary Collection     X X X X X X 
Adverse Events  X  X X X X X X 
Concomitant therapy  X X  X X X X X X 
 Table 2 is continued on the next page.  
 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518703], Inc.  CONFIDENTIAL  Page 40 of 62 Table 2 b (Continued): Group 1 and Group 2 Subset Schedule of Events   
Procedure  Maintenance  End of Treatment  
 Survival 
Follow -up 
   Visit 10 Visit 1 1 Visit 1 2 
Day 85  
Week 13   
(+/-3 days)  Day 92  
Week 14   
(+/-3 days)  Day 99  
Week 15   
(+/-3 days)  Day 180  
Visit 13   
(+/- 7 days)  Month s 9 & 
[ADDRESS_518704] TURBT; If subject not recovered, evaluations will be repeated every [ADDRESS_518705] injection of NanoDoce;  
4. Comprehensive  physical examination required at screening and End of Treatment; targeted physical exam at all other visits, if required;  
5. Comprehensive physical examination and ECOG to be performed at Visit 2 if not completed within the 14 days prior to Visit 2;  
6. Vitals will be performed prior to and post NanoDoce direct injection and intravesical instillations (see Section 7.3);  Temperature measurement is not required during the Visit [ADDRESS_518706] injection and 
instillation vitals monitoring;  
7. See Table 4 for Visits 2, 3 and 4 detailed PK collection schedule;  
8. PK samples will be collected within 24 hours prior to study drug intravesical instillation,  or can be drawn to coincide with laboratory sample collection prior to the Induction and Maintenance 
intravesical instillation visit, if within allowable visit window;  
9. Laboratory testing (CBC and Urinalysis) to be performed and results reviewed prior to all Induction and Maintenance intravesical instillations. Chemistry and coagulation to be collected only at 
visits 1, 4, 10 and End of Treatment . Any tissue sample collected during the study will be processed per Institution pathology procedure;  
10. Cystoscopy and cytology required at Visits 4, 10 and E nd of Treatment ; ad-hoc cystoscopy, urine cytology, and ‘for- cause’ biopsy can be conducted at any time during the study as needed, but 
must be  performed prior to any NanoDoce instillation;  
11. Any tissue sample collected during the study, starting with eligible TURBT tissue samples to be processed per Section [IP_ADDRESS] ; 
12. Chart review or subject contact . 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518707], Inc.  CONFIDENTIAL  Page 41 of 62 Table 3: Group 2 ( MIBC)  Schedule of Events   
Procedure  Screening  Treatment  
End of Treatment  Survival Follow -
up 
   Visit 1 Visit 2  Visit 3 
Days (-30 - 0) Day 1  Day 15  
(+/- 1 day)  Day 45  
(+/- 5 days)  Month s 6, 9, 12   
Informed Consent  X     
Medical and Surgical History1 X     
Demographics  X     
Physical Examination2 X X3  X  
ECOG  X X3  X  
12-Lead ECG  X   X  
Vital Signs4 X X  X  
Height and Weight  X     
Pharmacokinetic Collection5  X X X  
Laboratory Tests6 X  X X  
NanoDoce ® Direct Injection   X    
NanoDoce ® Intravesical 
Instillation  X    
TURBT   X    
Cystoscopy [ADDRESS_518708] injection of NanoDoce;  
2. Comprehensive physical examination required at screening and End of Treatment or early withdrawal; targeted physical exam at all other visits, if required;  
3. Comprehensive physical examination and ECOG to be performed at Visit [ADDRESS_518709] injection and intravesical instillations (see Section 7.3) ; 
5. See Table [ADDRESS_518710] ion schedule;  
6. CBC and Urinalysis) to be performed and results reviewed prior to the Visit 2 Injection and the intravesical instillations. C hemistry and coagulation to be collected at visits 1 and End of 
Treatment;  
7. Any tissue sample collected during the study will be processed per Institution pathology procedure;  
8. Any tissue sample collected during the study, starting with eligible TURBT tissue samples to be processed per Section [IP_ADDRESS] ;  
9. Chart review or subject contact . 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518711], Inc.  CONFIDENTIAL  Page 42 of 62 Table 4: Schedule of Pharmacokinetic Sample Collection  
Timepoint   Post Dose  
0 Hour  1  1 Hour (+/-10 min)  2 Hours (+/-10 min)  6 Hours (+/-20 min)  24 Hours (+/-30 min)  
Visit 2  2  X 3 X X X X 
Visit 3 2, 4  X     
Visit 4 5  X 6 X X X X 
Visit 5 -13 X     
1. PK sample collection to occur prior to administration of study drug for Visit 2 and Visit 4, and during Visit 3 (where no study drug is  administered);  
2. Groups 1 and 2;  
3. PK sample collection within [ADDRESS_518712] injection or anytime during the screening period;  
4. Even though there is a [ADDRESS_518713] the Day 15 sample on  Day 15.  
5. Group 1 and Group 2 subset only;  
6. PK sample collection within 24 -hours prior to the Visit 4 study drug intravesical instilla tion; or can be drawn to coincide with l aboratory sample collection prior to the 
Induction intravesical instillation . 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518714], Inc.  CONFIDENTIAL  Page 43 of 62 7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  
Sponsor acknowledges that injection of NanoDoce  into the resected bladder tumor , including the anesthesia 
necessary for the injection,  may qualify as a sensitive procedure and as such should be mentioned in this section.   
7.5 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the case report f orms 
(eCRFs). For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinician. Medications to be reported in the e CRF are concomitant prescription 
medications, over -the-counter  medications, and non- prescription medications  taken by [CONTACT_411237], whether  or not 
acute . 
Medications allowed in the study will include: local anesthetic  gel for catheter placement, prophylactic antibiotics 
(pre-or post TURBT) for infection prevention , methylene blue or other staining agents to enhance diag nostic 
visualization procedures and institution SOC IV chemotherapy (if required following Visit [ADDRESS_518715] injection and 
intravesical instillation).   
Group [ADDRESS_518716] been conducted using  NanoDoce , docet axel is a CYP3A4 substrate metabolized 
by [CONTACT_9058]  P450 isozyme CYP3A4 (Tax otere Package Insert) . In vivo  studies showed that the exposure of 
docetaxel increased 2.2- fold when it was co -administered with ketoconazole, a potent inhibitor of CYP3A4. Protease 
inhibitors, particularly ritonavir, may increase the exposure of docetaxel. Concomitant use of docetaxel  and drugs 
that inhibit CYP3A4 may increase exposure to docetaxel and should be a voided.  
7.6 P RECAUTIONARY MEDICATIONS, TREATMENTS, AND P ROCEDURES   
No precautionary medications, treatments, or procedures are included in this protocol; they may, however, be 
administered at the discretion of the Investigator , anesthesiologist, or the su bject’s primary care provider or 
oncologist . All medications will be recorded . 
7.7 PROHIBITED MEDICATIO NS, TREATMENTS, AND PROCEDURES  
Any dis tending media (conductive fluids, nonconductive or non- electrolyte and gas) other than isotonic saline or 
sterile water , are not allowed .  
For subjects in Group 1, the use of chemotherapy, immunotherapy, or radiation therapy is prohibited d uring the 
Induction period (a t Visit 4 or later ) or anytim e during the maintenance period.   
7.[ADDRESS_518717] of care allergy prophylaxis may be administered, at the discretion of the 
investigator . 
Dexamethasone use suggested:  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518718], Inc.  CONFIDENTIAL  Page 44 of 62 Visit 2: Subjects in Groups [ADDRESS_518719] injection dose only.  
Induction and Maintenance Intravesical Instillations: Subjects in Group 1 and Group 2 subset will take one 4 
mg dexamethasone tablet 12 hours before NanoDoce intravesical instillation, one 4 mg dexamethasone 
tablet 1 hour before NanoDoce intravesical instillation, and one 4 mg dexamethasone tablet 8 hours after 
NanoDoce intravesical instillation.   
Prophylactic antib iotics and any other prophylactic medications will be administered according to the institution’s 
SOC at any time during the study. 
7.9 RESCUE MEDICATIONS, TREATMENTS, AND PROC EDURES  
Rescue medications, treatments, and procedures are not expected for this study.  
7.10 PARTICIPANT ACCESS T O STUDY DRUG AT STUDY CLOSURE  
Not applicable.  
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAF ETY PARAMETERS  
Safety assessments to be conducted in this study include:  
• AE, collected at all study visits from the time of first study drug  dose; 
• Changes in concomitant medications ;  
• Findings from physical examinations ; 
• Changes in v ital signs ; and 
• Changes in laboratory parameters . 
Safety will be reviewed b y the Medical Monitor in an ongoing manner via the EDC system, and details will be 
confirmed at routine on -site monitoring visits.   
Safety and t olerability will be assessed by [CONTACT_411238].   
Included in the DSMB’s review of the AEs and general study data pertaining to safety there will be rules for non-
escalation . Any AE that is considered related or probably related to NanoDoce  is potentially a DLT. The definition of a 
DLT will be made by [CONTACT_411239], Sponsor Medical Director, and Principal Investigator [INVESTIGATOR_411206] . 
Events of special interest (Section 8.4.4) will be specifically reviewed and will form part of the review between doses , 
and the DSMB review will provide and document oversight as detailed in the DSMB Charter . 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518720], Inc.  CONFIDENTIAL  Page 45 of 62 8.1.1  DEFINITION OF ADVERS E EVENTS  (AE)  
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical 
product that which does not necessarily have a causal relationship with this treatment.  An AE can therefore be any 
unfavorable and unintended change in structure, function, sign, or symptom temporally associated with the use of a medicinal product, whether or not related to the product.  Undesirable changes in laboratory values should not be 
considered AEs unless they are considered symptomatic of a clinical condition or diagnosis, are evaluated as clinically 
significant , or require therapy.  Worsening of a pre -existing condition is also considered an AE , as is the discovery of 
an abnormal finding during a physical exam that was not included in the m edical history.  Clinical conditions 
attributable to disease progression will be considered AEs .  
8.1.2  DEFINITION OF SERIOU S ADVERSE EVENTS  (SAE)  
A Serious Adverse Event  (SAE) is any adverse event that meets at least one of following criteria:  
1) Is fatal;  
2) Is life -threatening ; in the opi[INVESTIGATOR_871], the subject was at substantial risk of dying at the time 
of the adverse event, or use or continued use of the medical product might have resulted in the death of the 
patient ; 
3) Is a persistent or signi ficant disability or incapacity;  
4) Requires hospi[INVESTIGATOR_43928].  Hospi[INVESTIGATOR_411207] > 24 
hours, or a hospi[INVESTIGATOR_411208] (non -
diagnostic);  
5) Exposure prior to conception or during pregnancy may have resulted in a congenital anomaly or birth defect  
in the child ; 
6) Other important medical  events not noted in events above, but may be considered a serious experience 
when, based upon appropriate medical judgment, may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes as listed in #1 -5 in this definition.  
8.1.3  DEFINITION OF UNANTI CIPATED PROBLEMS  (UP)  
As this is a Phase 1/2 study , all unanticipated problems will be captured as either AEs or SAEs and will be defined and 
reported accordingly.  
8.2 CLASSIFICATION OF AN  ADVERSE EVENT  
 
8.2.1  SEVERITY OF EVENT  
Signs and symptoms will be graded by [CONTACT_57746], moderate, severe, l ife-threatening , or fatal  according 
to the following definitions:  
• Mild:   The AE is transient and does not interfere significantly with the subject’s normal functioning level. The 
AE resolves spontaneously or may require minimal therapeutic intervention;  
• Moderate:   The AE produces limited functional impairment and may require therapeutic intervention. The 
AE produces no sequelae;  
• Severe:   The AE results in significant impairment of function and may lead to temporary inability to resume 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518721]’s normal life pattern. The AE produces sequelae which require prolonged therapeutic 
intervention ; 
• Life-Threatening:   The AE results in life -threatening consequences, urgent intervention is indicated, urgent 
operative intervention is indicated or the patient is at risk of death at the time of the event if immediate 
intervention is not undertaken; 
• Fatal:  The AE results in death . 
Further, t oxicities should be evaluated according to the NCI CTCAE, version 4 .0 criteria.   
8.2.2  RELATIONSHIP TO STUDY DRUG 
 
The following five -point scale will be used by [CONTACT_411240] : 
 
• Definitely related: A clinical event (including laboratory test abnormality) occurring in a plausible time 
relationship to drug administration, and which cannot be explained by [CONTACT_113395]. The response to withdrawal of the drug (de -challenge) should be clinically plausible. The event 
must be definitively associ ated pharmacologically, using a satisfactory re -challenge procedure, if necessary;  
 
• Probably related: A clinical event (including laboratory test abnormality) with a reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on withdrawal (de -challenge). Re -challenge information is not 
requ ired to fulfill this definition;  
 
• Possibly related: A clinical event (including laboratory test  abnormality) with a reasonable time sequence to 
administration of the drug, but which could also be explained by [CONTACT_113395]. Information on drug withdrawal may be lacking or unclear;  
 
• Unlikely to be related:  A clinical event (including laboratory test abnormality) whose temporal relationship 
to drug administration makes a causal relationship improbable (e.g., the event did not occur within a 
reasonable time after administration of the trial medication) and in which other  drugs or chemicals or 
underlying disease provides plausible explanations (e.g., the participant’s clinical condition , other 
concomitant treatments);  
 
• Not related: An event for which sufficient information exists to conclude that the etiology of the event is unrelated to the study drug. An alternative definitive etiology should be documented by [CONTACT_14520] . 
 
8.2.[ADDRESS_518722] 
but that i n itself does not qualify as unexpected; review against information available and provided for the study 
drug  is what will determine expectedness.  
Sponsor will be responsible for determining whether an AE is expected or unexpected. An AE will be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study drug , in the protocol and within the Investigator’s Brochure.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518723], Inc.  CONFIDENTIAL  Page 47 of 62 8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLO W-UP 
AE will be recorded throughout the study and at early termination and  will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA).  Adverse events ongoing at the final study visit must be followed until resolution or 
until the Investigator determines them to be stable and /or adequately managed.   
Subjects will be required to spontaneously report any AE s. Study personnel will ask open- ended questions to obtain 
information about AEs at every visit.  Date and time of onset and resolution (if applicable) of the AE will be 
documented.  
All SAEs must be followed until the event resolves or, in the opi[INVESTIGATOR_689], become stable.   
The Sponsor will report any serious, unexpected and drug -related AE to applicable regulatory agencies and provide  
these reports to the investigative sites.  The Investigator must promptly inform the IRB of such events and retain a 
copy of the notification in the Investigator Site File (ISF) . 
8.[ADDRESS_518724] study drug dose (injection) until [ADDRESS_518725] study drug dose (injection or 
instillation)  for Group 2 subjects or until the End of Treatment ( Visit 13) visit for Group 1 or Group 2 subset subjects.  
All AEs (whether or not attributable to the study  drug ) occurring during the st udy observed by [CONTACT_411241].  The following information will be recorded for all AEs: 
• Event: name/c ondition/diagnosis/description ; 
• Onset and resolution time and/or date ; 
• Severity ; 
• Relationship to study  drug ; (assessment by [CONTACT_411242]),  
• Action taken ; 
• Seriousness .  
8.4.[ADDRESS_518726] be reported to the Medical Monitor  immediately upon discovery of the event, using 
the SAE report form, by [CONTACT_411243], if necessary, by [CONTACT_309726]:  
[CONTACT_411260] ony Verco  
Medical Monitor  
E-mail:  [EMAIL_7840]  
Phone : 805- 235-9193  
Fax: [PHONE_8490] 
 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518727] s: Gere diZerega, MD  or Antony Verco, MD  
 Medical Director   Medical Monitor  
 805- 630- 2800   805- 235- 9193  
The S ponsor will advise the Investigator regarding the nature of any further information or documentation that is 
required.  The Investigator should provide the following documentation at the time of notification if available:  
• SAE Report Form;  
• Concomitant and su pport medication pages;  
• Relevant diagnostic reports;  
• Relevant laboratory reports;  
• Admission Notes;  
• Hospi[INVESTIGATOR_44458] (when available).  
8.4.[ADDRESS_518728] will be signs of systemic toxicity due to docetaxel  exposure; particularly from bladder injection. 
NanoDoce has never previously been injected in the bladder ; subjects will be monitored for injection site pain and 
any reported event , in particular , during the first [ADDRESS_518729]’s sexual partner during the study or within [ADDRESS_518730]  as soon as the  Investigator is aware of it.  The pregnancy will not 
be considered an SAE; however , information on the  event  will be collected and the outcom e followed to birth or 
termination of pregnancy.  
Any pregnancy complication or premature terminations including miscarriage, spontaneous abortion, or elective 
termination of a pregnancy for medical reasons will be reported as an SAE, as described in Sectio n 8.4.2.  Should the 
pregnancy result in a congenital anomaly or birth defect, a separate SAE report must be submitted.  Furthermore, all 
neonatal deaths that occur within [ADDRESS_518731] to causality.  In 
addit ion, any infant death that occurs after the 30 -day reporting period that the I nvestigat or suspects is related to 
the in -utero exposure to the study treatment should also be reported.  
8.5 STUDY HALTING RULES  
This study is a Phase 1/[ADDRESS_518732] received treatment  will be followed to the completion of  the End of Treatment visit  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518733], Inc.  CONFIDENTIAL  Page 49 of 62 or 45 days after administration of  NanoDoce , whichever occurs later, to ensure all safety data is collected on all 
treated subjects . 
DSMB may determine that a further three subjects should be treated  at the same dose  as the current cohort , to 
provide additional safety and/or tolerability information as needed in order to determ ine if dose  escalation should 
proceed; they may also determine that it is acceptable to proceed with an increased dose  in the next cohort; or they 
may determine that the safety and tolerability profiles are not acceptable and may stop the study.  
The S ponsor is responsible for notifying FDA of any temporary halt to the study or when the  study is terminated;  the 
Investigator  will be required to notify the IRB accordingly.  
8.[ADDRESS_518734] entered in  the database  and prior to 
proceeding to dose escalation . See [IP_ADDRESS]  
Prior to dose escalation proceeding, the DSMB will convene to review the cohort data, and generate a report 
outlining any safety concerns from the reviewed  EDC data. This review will take place prior to proceeding with either 
addition of more subjects to a current cohort or proceeding to dose escalation in a new cohort.  
During the DSMB review , members will review all EDC safety data available; provided  as reports generated directly 
from the EDC system and by [CONTACT_941] D ata Management group. Emphasis  will be placed  on the events of special interest 
as outlined in Section 8.4.4,  on emerging safety trends or events which may constitute dose limiting toxicities  as 
outlined in Sections 6.1.[ADDRESS_518735]’s complete and comprehensive medical and research study records, Investigator Site 
File, pharmacy document and any other applicable documents as needed to assure that the conduct of the study and 
the safety of the study subject is maintained and within  compliance.  In addition, FDA or other government agencies 
may request an inspection, following notification to the site.  In such an event, the Inv estigator agrees to notify the 
Sponsor immediately, or at the earliest possible opportunity of the request . The clinical trial site will allow access to 
the inspectors to review requested records. 
US Biotest will conduct a site initiation visit  to provide the Investigator and study staff with a comprehensive 
overview of the protocol and study procedures and to review mutual obligations and requirements of regulatory 
authorities.  The Investigator  Site File (may be identified as regulatory file or binder ) containing required 
documentation will be up to date throughout the life of the study and maintained at the site  for reference and 
inspection.  
Routine monitoring visits will be conducted to assure compliance with the study protocol  and regulatory 
requirements , to review and verify  the subject’s eCRF by [CONTACT_411244], to ensure adequate 
records of clinical supplies are maintained, and to assess the continued suitability of the investigational site. On 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518736] , destroyed or retained at the site . 
 
10 STATISTICAL CONSIDER ATIONS  
 
10.1 STATISTICAL AND ANAL YTIC AL PLANS  
A formal Statistical Analysis Plan  (SAP) will be prepared for this trial , and the SAP will be signed off prior to study 
database lock. 
10.2 STATISTICAL HYPOTHES ES 
No formal statistical inference (i.e. , “p-values”) will be applied.  The results of this trial will be based on descriptive 
statistics only.  
10.[ADDRESS_518737] one  dose of study drug  will be 
included i n the descriptive analysis.   
The dose populations will be defined in the SAP once the patt ern of exposure is determined i.e. the dose and the 
total number of treatments.  The medical team will provide guidance on the groupi[INVESTIGATOR_14839].  The resulting displays will 
provide the basis for interpreting possible dose -response outcomes for both safety and any  possible signals of 
efficacy.  This will be supported by [CONTACT_411245] . 
10.3.1 MISSING DATA  
Data will be presented as observed and no missing data imputation will be performed. All effort will be made to 
capture sufficient in formation to allow for medical interpretation of the results.  
10.4 DESCRIPTION OF STATI STICAL METHODS  
 
10.4.1  GENERAL APPROACH  
The focus of the trial will be on the safety and tolerability of the dose -escalated treatments.  The general approach 
will be to highlight any trends that cause concern for the reviewing medical monitoring team (i.e. , dose -limiting 
toxicities -DLTs).   
10.4.2  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T(S)  
Not a pplicable. The primary objective is to evaluate the safety and tolerability as demonstrated by [CONTACT_117795], changes in 
laboratory assessments, physical examination findings and vital signs.   
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518738], Inc.  CONFIDENTIAL  Page 51 of 62 10.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
Secondary endpoints will be summarized descriptively.  These will include supportive informat ion to provide context 
for the dose(s) chosen to move forward for future study , as follows:   
• Concentration of docetaxel  in the systemic circulation post -injection in the presence of intravesical 
instillation (as determined by [CONTACT_411212] ); 
• Disease progress ion as defined by [CONTACT_113511], cytology, and if indicated, biopsy at Visit 10  (Group1 and 
Group 2 subset)  and Visit 13  in Group 1  or Group 2 subset .  
• OS will be determined for all groups at Month s 6 (Group 2 only) , 9 and 12. 
See also Section 10.4.11, Exploratory Analyses, for further details.  
10.4.4  SAFETY ANALYSES  
 
[IP_ADDRESS]  ADVERSE EVENTS  
AE recorded during the trial will capture medically relevant changes found during the physical exam, and medically 
relevant changes in vital signs and laboratory analytes found during  the trial.  In addition , spontaneously reported or 
observed events will be recoded  
Events reported at or after the first injection o f NanoDoce  will be considered TEAE . All reported events will be listed 
by [CONTACT_411246], investigator term, MedDRA coded term, date/study day (from initial 
treatment) for onset and cessation, severity (using the NCIC severity grading ), and  relationship to study medication. 
Only the TEAE will be tabulated.  
The primary safety analysis and clinical study report will be based on the data collected up to the  End of Treatment 
visit. Additional tabulations including safety data up to and including the 6 -month follow -up visit will also  be presented.  
The focus of the summary will be on the treatment/dose group for the subject.  
Adverse event reports will be coded u sing the most recent version of MedDRA, signed off by [CONTACT_1689], 
and presented by s ystem organ class and preferred term.  All AE and abnormal laboratory variables will be assessed 
according to the NCI -CTCAE v4.0 grading system. The number of subje cts reporting,  and number of events reported 
will be presented in frequency tables (overall, by [CONTACT_2236], by [CONTACT_411247]) for each dose cohort  in 
each group . Adverse events of special interest will be presented separately.  The criteria for the most frequently 
reported events will be determined in the SAP after reviewing the data; due to the small dose cohorts, the traditional 
5 and 10% would not be reasonable.   
[IP_ADDRESS]  LABORATORY A NALYTES  
Quantitative laboratory data will be su mmarized as mean values and change from screening scores (i.e. , change = 
time point -screening) presented by [CONTACT_411248].  For tests with normal range provided, 
the clinical status and its change from screening (Normal/High Abnormal/Low Abnormal) will be summarized using 
shift tables for each dose group.  Analytes of interest  (e.g., hematological tests) may be graphed by [CONTACT_411249]; these special analytes will be confirmed in the SAP.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518739], Inc.  CONFIDENTIAL  Page 52 of 62 [IP_ADDRESS]  VITAL SIGNS  
Vital signs (systolic and diastolic blood pressure, heart rate,  respi[INVESTIGATOR_697]  (if measured by [CONTACT_8236]) , 
temperature ) and body weight  will be tabulated and mean raw values and changes from baseline scores (change = 
baseline -visit) where baseline is the last measurement prior to the study drug  application, for each treatment group.  
[IP_ADDRESS]  ECOG  
The ECOG scale will be tabulated by [CONTACT_411250].  
10.4.5  ADHERENCE AND RETEN TION ANALYSES  
All subjects who enter the trial will be accounted for and any reasons for early termination noted, including disease 
progression.   
10.4.6  BASELINE DESCRIPTIVE  STATISTICS  
Complete demographic and baseline data will be tabulated.  The medical history, which will be coded in MedDRA, will 
be presented.  The disease history data, with a focus on the previous treatment and current staging, and the 
information collected on the procedure  to apply the treatment will also be summarized.   
10.4.7  PLANNED INTERIM ANAL YSES  
There are no formal interim analyses planned.  There will be an ongoing safety and tolerability review by [CONTACT_411251] .  
[IP_ADDRESS]  SAFETY REVIEW  
Safety data will be reviewed in a combination of Medical Monitor reviews and DSMB ( based on the DSMB c harter ) 
meetings. Safety reviews will be conducted on an ongoing basis to allow for ‘real -time’ safety assessment.  
Group 1:  
Reviews will be conducted by  [CONTACT_82559] a ll clinical data from subjects in each cohort, on an ongoing 
basis and once each subject has completed Visit 4, Visit 6, and Visit 9. Additionally, depending on enrollment rate, 
during direct injection escalation  phase,  the Medical Monitor  will conduct monthly reviews if  more than [ADDRESS_518740], in each cohort, including all DLTs (See section 8.1) and 
excluding PK, will be reviewed and evaluated to determine if the dose is safe and tolerable, up to and including the 
first day of the induction period instillation, or Visit 4. The Medical Monitor will provide an aggregate summary 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518741] injection dose escalation (Cohorts 2, 3 and 4). 
At the 2nd review, all clinical data from each subject in that cohort, including all DLTs (Section 8.1) and excluding PK, 
will be reviewed and evaluated up to, and including the fourth induction period instillation, or Visit 6. This will allow 
an assessment of safety prior to increasing the intravesical instillation dose from 2.0 mg/mL to 3.0 mg /mL,  
 Group [ADDRESS_518742] in a Group 2 cohort reaches 
Day 45 before the same dose is evaluated in Group 1, the dose escalation in Group 2 will be based on the relevant 
clinical data available in that Group 2 cohort.   
Groups 1 and 2  
In addition, the Medical Monitor  will provide an aggregate data report to the DSMB every 3 months. A formal DSMB 
meeting will be conducted, at any time during the study if required or requested by [CONTACT_411252].  
[IP_ADDRESS]  EFFICACY REVIEW  
Cystoscopy and biopsy (if available), and any institution -required diagnostic ima ging will be reviewed at End of 
Treatment  visit for Group 1  and Group 2 subset . For Group s 1 and  2, histologic evaluation of tissue samples will be 
assessed for presence of tumor, if any.  Review may be earlier if there is persistence, recurrence and progression of disease .  
10.4. 8 ADDITIONAL SUB-GROUP ANALYSES  
Subjects who perform particularly well (i.e. , experience minimal AEs) may be compared to those who perform more 
poorly.  This topic, and the criteria for defining each group, will be detailed in the SAP.  
10.4.9 MULTIPLE COMPARISON/ MULTIPLICITY  
Not applicable, as no inferential analyses wi ll be employed.   
10.4.10  TABULATION OF INDIVI DUAL RESPONSE DATA  
All data collected in the eCRF will at a minimum be listed; listings will support the tabulated data/outcomes.  
10.4.1 1 EXPLORATORY ANALYSES  
Determination of immune response in the bladder lesion due to NanoDoce injection and instillation by [CONTACT_411253]/biopsy samples  at any time during the study; baseline TURBT samples will be 
concurrently evaluated.  
 
10.4.12  CONCOMITANT MEDICATION  
All medication taken during the trial will be, at a minimum, listed with the start and stop  dates . For this small clinical 
trial, the medications will not be coded using the WHO Drug Dictionary.  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518743], Inc.  CONFIDENTIAL  Page 54 of 62 10.5 SAMPLE SIZE  
There is no formal sample size calculation for this Phase I/II safety study. To provide a reference for the ongoing 
safety review of each cohort and the possible expansion of a cohort with safety concerns, the procedure “confidence interval for the probability of observing a rare event”  was employed in nQuery Advisor (Version 8) to determine that, for an event with an occurrence rate of 0.33, the probability of detecting it with 3 subjects is 69.9% vs 91.0% for 6 subjects, and for an event rate of 0.05 the probabil ity of detecting the event is 14.3% and 26.5% for 3 and 6 
subjects, respectively.  
The rationale to expand the final cohort in the Dose Confirmation Phase to 12 subjects, from either 3 or 6 subjects, was based on the “reasonable gain” in detection rate that  each additional subject would provide in this early phase 
exploratory trial. The calculations were performed as the estimates above. With 12 subjects , the probability of 
detecting the 0.1 event rate is 71.8% , as compared to a 46.9% probability with 6 subj ects. This sample size also allows 
for more acceptable probabilities  of detecting much rarer events: for example, a 46% probability of detecting an 
event with a 0.05 event rate (compared to  26.5% with 6 subjects), and a 11.4% probability for an event with a 0.01 
event rate (5.9% with 6 subjects ).    
10.6 MEASURES TO MINIMIZE BIAS  
 
10.6.1  ENROLLMENT/ RANDOMIZATION/ MASKING PROCE DURES  
Not applicable.  
10.6.2  EVALUATION OF SUCCESS OF BLINDING  
Not applicable.  
10.6.3  BREAKING THE STUDY BLIND/ PARTICIPANT  CODE  
Not applicable.   
11 SOURCE DOCUMENTS AN D ACCESS TO SOURCE D ATA/DOCUMENTS  
An eCRF is required and must be completed for each consenting  and enrolled subject by [CONTACT_15953].  All data in the eCRF must reflect the corresponding source document. Any correction to eCRF entries 
must be reflect ed in a valid ated  audit trail.  Only data required by [CONTACT_411254] . 
The Investigator must maintain adequate and accurate source documents on which the eCRFs for each subject are 
based.  They will be separate and distinct from the eCRFs.  These records should include detailed notes on:  
• The medical history prior to the subject’s involvement in the study;  
• Date of informed consent;  
• The basic identifying information that links the subject’s medical record with the eCRFs;  
• Screening, enrollment, end of treatment and safety visit  details including dates and reasons for early 
termination;  
• The results of all diagnostic tests performed, diagnoses made, therapy provided, and any other data on the 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518744] ; 
• The medical condition during the subject’s involvement in the study;  
• All AEs; 
• The subject’s exposure to the study medication;  
• The subject’s exposure to any concomitant therapy;  
• All relevant observations and data on the condition of the subject throughout the trial;  
• Justification for all entries in the subject’s eCRF .  
[ADDRESS_518745] to its 
accuracy, authenticity, and completeness. 
The EDC application  being used in this study is TrialMaster® version 4.2.1 from OmniComm Systems. TrialMaster 
studies are hosted from a state- of-the-art data center with rigorous physical and electronic security. All data is 
backed up daily to Iron Mountain, in Ohio and is also backed up to a hurricane -proof bunker in Fort Lauderdale, 
[LOCATION_012]. OmniComm has is  certificated  with European “Safe Harbor” regulations  (all necessary measures are in place 
to protect patient confidentiality even with the data being stored in a US data center ). The data management and 
statistical CRO, McDougall Scientific Ltd., ensures that the development of the eCRF follows their SOPs which are 
based on the Systems Development Life Cycle (SDLC) methodology . Access to the system is restricted by [CONTACT_411255]; these are controlled by [CONTACT_411256].  All personnel using the system will be trained and 
the training documented.  All changes to the database are recorded in an audit trail.  The database will be locked 
when all outstanding queri es have been addressed, all agreed -to data is marked as source -verified, and the PI [INVESTIGATOR_411209].   
All software applications used in the collection of data will be properly validated following standard computer system 
validation that is compliant with all regulatory requirements.   
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 
13.[ADDRESS_518746]  
Before the start of the study, the study protocol, informed consent form and/or other appropriate documents will be 
submitted to the IRB and/or the authorities in accordance with local legal requirements.  It is the responsibility of the 
Investigator to assure that all aspects of the IRB review are conducted in accordance with current regulations.  US 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518747] to the same requirements as the original protocol.  All changes to the 
consent form will be IRB -approved; a determination will be made regarding whether previously consented 
participants need to be re -consented  by [CONTACT_1201] . 
13.3 INFORMED CONSENT PROCESS  
 
13.3.1  CONSENT/ ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANT S 
Subjects being considered for participation in this study will be provided an informed consent form (ICF) to read and 
sign before being permitted to participate.  The ICF will describe the study drug  and any prior findings from previous 
studies ; study proce dures including the timing of study clinic visits and responsibility  to adhere to those timelines ; 
any risks which may be associated with the study drug  or the procedures being carried out  in the study; and all other 
items required under [ADDRESS_518748] enrolled in the study, in accordance with the U.S. 
Food and Drug Administration (FDA) regulations [ADDRESS_518749] th ose changes ; in which case, it is the 
responsibility of the Investigator to ensure that an amended consent is approved by [CONTACT_411257] , as well as those subsequently entered in the study, if required by [CONTACT_1201] . 
The terms of the consent and when it was obtained must also be documented in the eCRF.  The original, signed 
informed consent document must be maintained on file at the study site and be made available for review during monitoring visits and site audits.  
13.4 PARTICIPANT  AND DATA CONFIDENTIALITY  
All local legal requirements regarding data protection will be enforced. All study findings and documents will be 
regarded as confidential.  The Investigator and members of his/her research team must not disclose such information 
without prior written approval from US Biotest.   
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518750] by [CONTACT_73976]  (if allowed by [CONTACT_14189], local and/or state requirements) , birth date,  and subject number.  
The subjects will be informed  that all study findings will be stored and handled in strictest confidence, according to 
legal requirements, and that authorized research I nvestigators and agents of the FDA , the NCI , and authorized 
personnel  or delegates  of US Biotest have the right to inspect their medical records. 
13.4.[ADDRESS_518751] (EMR) data 
management system that is 21CFR Part 11 compliant  and meets all regulatory requirements , regulations and quality 
standards . 
For paper source, documentation  is expected to be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black or blue ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014].  
Source documents will be  maintained for recording data for each participant enrolled in the study. Data reported in 
the eCRF derived from source documents should be consistent with the source documents . Any  discrepancies should 
be explained and captured in a progress note and maintained in the subjec t’s official electronic study record . 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518752] maintain study documents:  
• For a minimum of two years following the date the marketing application (NDA) is approved for the 
indication for which the drug was investigated;  
• For a minimum of two years following the release date of the final report, if no ma rketing application is to 
be filed, or if the marketing application is not approved for the indication of which the drug was 
investigated or is discontinued,  and FDA has been notified; or,  
• For a minimum of [ADDRESS_518753] obtain the S ponsor’s written permission before transferring or disposing of any records.  
14.3 PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Cl inical Practice (GCP) , or FDA or IRB 
requirements. The noncompliance may be on the part of the participant, the Investigator, or the study site staff. As a 
result of deviations, corrective actions are required and expected to be implemented promptly by [CONTACT_779] . 
These practices are consistent with ICH E6:  
 
• 4.5:  Compliance with Protocol, Sections 4.5.1, 4.5.2, 4.5.3 and 4.5. 4  
• 5.1:  Quality Assurance and Quality Control, Section 5.1.1  
• 5.20:  Noncompliance, Section s 5.20.1, and 5.20.2.  
It is the responsibility of the site to use continuous vigilance to identify and report deviations as soon as possible 
after occurrence. All deviations must be addressed in study source documents, and reported to  the Sponsor , the 
Data Management group  and to the local IRB , per guidelines. The site PI/study staff is responsible to  adher e to any 
IRB reporting requirements.  
Serious site non-compliance and an inability of the Sponsor to bring the site back into compliance, will be reported to 
FDA in accordance with their requirements.   
14.4 PUBLICATION AND DATA SHARING POLICY  
By [CONTACT_33351], the Investigator agrees with the use of results of the study for the purposes of national and international registration, public ation, and information for medical and pharmaceutical professionals.  If 
necessary, the authorities will be notified of the Investigator's name, address, qualifications, and extent of 
involvement.  The S ponsor will prepare an integrated clinical/statistical report. Publication/presentation of data is  not 
allowed without explicit permission from US Biotest, Inc. Submission of data for publication/presentation will be 
coordinated and approved by [CONTACT_411258].  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518754], Inc.  CONFIDENTIAL  Page 59 of 62 The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials 
registratio n policy as a condition for publication. The ICMJE defines a clinical trial as any research project that 
prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause -
and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, 
surgical procedures, devices, behavioral treatments, process -of-care changes, and the like. Health outcomes include 
any biomedical or health -related measures obtained in subjects  or participants, including pharmacokinetic measures 
and AE. The ICMJE policy, and the Section [ADDRESS_518755] -party liability insurance coverage in accordance with all local le gal 
requirements.  This insurance will cover all parties involve d in the trial including, but not necessarily limited to, the 
principal investigator, clinical trial site, and subjects.   
  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518756], Inc.  CONFIDENTIAL  Page 60 of 62 18  LITERATURE REFEREN CES  
Albany C., Sonpavde G. Docetaxel for the treatment of bladder cancer. Expert Opin Investig Drugs. 2015;24(12):1657 -
64. 
 
Babjuk M., Bohle A., Burger M., Capoun O., Cohen D., Comperat E. M., et al. EAU Guidelines on Non- Muscle -invasive 
Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017 Mar;71(3):447 -61. 
 Babjuk M., Böhle A., Burger M., Compérat E., Kaasinen E., Palou J., et al. Guidelines on non- muscle -invasive bladder 
cancer (TaT1 and CIS). 2015.  
 Barlow L. J., Benson M. C. Experience with newer intravesical chemotherapy for high -risk non -muscle -invasive 
bladder cancer. Curr Urol Rep. 2013 Apr;14(2):65 -70. 
 
Barlow L. J., McKiernan J. M., Benson M. C. The novel use of intravesical docetaxel for the treatment of non -muscle 
invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009 Jun;27(3):331-
5. 
 
Barlow L. J., McKiernan J. M., Benson M. C. Long -term survival outcomes with intravesical docetaxel for recurrent 
nonmuscle invasive bladder cancer after previous bacillus Calmette -Guerin therapy. J Urol. 2013 Mar;189(3):834- 9. 
 Barlow L., McKiernan J., Sawczuk I., Benson M. A single -institution experience with induction and maintenance 
intravesical docetaxel in the management of non -muscle- invasive bladder cancer refractory to bacille Calmett e-
Guerin therapy. BJU Int. [ADDRESS_518757];104(8):1098 -102.  
 Dinney C. P., Greenberg R. E., Steinberg G. D. Intravesical valrubicin in patients with bladder carcinoma in situ and 
contraindication to or failure after bacillus Calmette -Guerin. Urol Oncol. 2013 Nov; 31(8):1635- 42. 
 
Hollister D., Jr., Coleman M. Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. JAMA. 
1980 Nov 7;244(18):2065- 7. 
 Laudano M. A., Barlow L. J., Murphy A. M., Petrylak D. P., Desai M., Benson M. C., et al. Long -term clinical outcomes 
of a phase I trial of intravesical docetaxel in the management of non -muscle -invasive bladder cancer refractory to 
standard intravesical therapy. Urology. 2010 Jan;75(1):134- 7. 
 Mak R. H., Hunt D., Shipley W. U., Efstathiou J. A., Teste r W. J., Hagan M. P., et al. Long -term outcomes in patients 
with muscle -invasive bladder cancer after selective bladder -preserving combined -modality therapy: a pooled analysis 
of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 1;32(34):[ADDRESS_518758] intraves ical therapy. J Clin Oncol. 
2006 Jul 1;24(19):3075 -80. 
 Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649- 55. 
Park J. C., Citrin D. E., Agarwal P. K., Apolo A. B. Multimodal management of muscle -invasive bladder cancer. Curr 
Probl Cancer. 2014 May -Jun;38(3):80- 108.  
 Smith Z. L., Christodouleas J. P., Keefe S. M., Malkowicz S. B., Guzzo T. J. Bladder preservation i n the treatment of 
muscle -invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013 
Jul;112(1):13 -25. 
 
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518759], Inc.  CONFIDENTIAL  Page 61 of 62 Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., Wehle M. Efficacy and safety of valrubicin for the 
treatment of Bacillus Calmette- Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 
2000 Mar;163(3):761- 7. 
 
Taxotere (docetaxel) Package Insert. [COMPANY_011] -aventis US LLC. Rev Dec 2015.  
 
TICE® BCG Package I nsert. Organon [LOCATION_003] Inc. Rev Feb 2009.  
  
Phase 1/2 NanoDoce® Trial  in Subjects with Urothelial Carcinoma   Version 7.[ADDRESS_518760], Inc.  CONFIDENTIAL  Page 62 of 62 APPENDIX  A: ECOG PERFORMANCE SCA LE 
Patient performance status will be graded according to the Eastern Cooperative Oncology Group (ECOG) scale* as 
described below.  
 
Grade  ECOG PERFORMANCE STATUS DESCRIPTION  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work  
2 Ambulatory and ca pable of all selfcare but unable to carry out any work activities. Up and about more 
than 50% of waking hours  
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
5 Dead  
 
* As published in Am. J. Clin. Oncol.:  
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity and Response 
Criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649 -655, 1982.   
 